PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24569990-4 2014 We identify the damage-inducible kinase, c-Abl, as the PKCdelta Tyr-155 kinase and c-Src as the Tyr-64 kinase. Tyrosine 64-67 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 41-46 24569990-4 2014 We identify the damage-inducible kinase, c-Abl, as the PKCdelta Tyr-155 kinase and c-Src as the Tyr-64 kinase. Tyrosine 96-99 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 41-46 24569990-7 2014 Expression of "gate-keeper" mutants of c-Abl or c-Src that are active in the presence of dasatinib restored phosphorylation of PKCdelta at Tyr-155 and Tyr-64, respectively. Tyrosine 139-142 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 39-44 24569990-7 2014 Expression of "gate-keeper" mutants of c-Abl or c-Src that are active in the presence of dasatinib restored phosphorylation of PKCdelta at Tyr-155 and Tyr-64, respectively. Tyrosine 151-154 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 39-44 24569990-8 2014 Imatinib, a c-Abl-selective inhibitor, also specifically blocked PKCdelta Tyr-155 phosphorylation. Tyrosine 74-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 12-17 24378532-4 2014 Furthermore, using a high-throughput src homology 2 (SH2) domain binding assay, the SH2 domain of ABL1 and the PI 3-kinse regulator subunit (PIK3R3) were identified as candidates for the binding partner of tyrosine-phosphorylated PLEKHG2. Tyrosine 206-214 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 98-102 24475245-3 2014 Tyrosine phosphorylation of ArgBP2, mediated by c-Abl kinase and counterbalanced by PTP-PEST phosphatase, regulates many of its interactions. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 48-53 23542172-0 2014 The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer. Tyrosine 17-25 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 43-48 24455116-4 2014 Imatinib binds to BCR-ABL kinase domain by preventing the transfer of a phosphate group to tyrosine on the protein substrate and the subsequent activation of phosphorylated protein. Tyrosine 91-99 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 18-25 23892407-16 2013 CONCLUSIONS: Inhibition of c-Abl inactivated IkappaBalpha/NF-kappaB pathway is associated with IkappaBalpha tyrosine phosphorylation in breast cancer cells. Tyrosine 108-116 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 27-32 24055812-7 2013 Phosporylations of the p85-bound Rho-GDP dissociation inhibitor-2 on 130 and 153 tyrosine residues by c-Abl and Src were required for the complex to be recruited to P-selectin glycoprotein ligand-1 and thereby regulate beta1 integrin-mediated T cell adhesion to vascular cell adhesion molecule-1. Tyrosine 81-89 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 102-107 23318434-7 2013 On the other hand, Abl interacted with the C-terminal domain of Myc and phosphorylated up to five tyrosine residues in its N-terminus, the principal of which was Y74. Tyrosine 98-106 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 19-22 23318434-10 2013 Thus, our data unravel two potential effects of Abl on Myc: first, Abl signaling can indirectly augment acetylation of Myc by p300, and most likely also its transcriptional activity in the nucleus; second, Abl can directly phosphorylate Myc on tyrosine: the resulting form of Myc appears to be cytoplasmic, and its presence correlates with Abl activation in cancer. Tyrosine 244-252 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 48-51 23318434-10 2013 Thus, our data unravel two potential effects of Abl on Myc: first, Abl signaling can indirectly augment acetylation of Myc by p300, and most likely also its transcriptional activity in the nucleus; second, Abl can directly phosphorylate Myc on tyrosine: the resulting form of Myc appears to be cytoplasmic, and its presence correlates with Abl activation in cancer. Tyrosine 244-252 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 67-70 23318434-10 2013 Thus, our data unravel two potential effects of Abl on Myc: first, Abl signaling can indirectly augment acetylation of Myc by p300, and most likely also its transcriptional activity in the nucleus; second, Abl can directly phosphorylate Myc on tyrosine: the resulting form of Myc appears to be cytoplasmic, and its presence correlates with Abl activation in cancer. Tyrosine 244-252 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 67-70 23318434-10 2013 Thus, our data unravel two potential effects of Abl on Myc: first, Abl signaling can indirectly augment acetylation of Myc by p300, and most likely also its transcriptional activity in the nucleus; second, Abl can directly phosphorylate Myc on tyrosine: the resulting form of Myc appears to be cytoplasmic, and its presence correlates with Abl activation in cancer. Tyrosine 244-252 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 67-70 24056763-6 2013 DNA damage-mediated tyrosine phosphorylation was required for MyoD recruitment to target genes, as the ABL phosphorylation-resistant MyoD mutant (MyoD Y30F) failed to bind the chromatin following DNA damage, while retaining the ability to activate transcription in response to differentiation signals. Tyrosine 20-28 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 103-106 23740246-11 2013 More importantly, Abi1 knockdown inhibited c-Abl phosphorylation at Tyr-412 and the interaction of c-Abl with CAS. Tyrosine 68-71 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 43-48 23892407-14 2013 Overexpression of c-Abl K290R in T47D and MBCDF cells reduced basal and DOX-induced NF-kappaB activation as well as IkappaBalpha tyrosine phosphorylation. Tyrosine 129-137 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 18-23 23645696-4 2013 Tyrosine phosphorylation of KAP1 is induced by several tyrosine kinases, such as Src, Lyn, Abl, and Brk. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 91-94 22976128-0 2013 Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells. Tyrosine 19-27 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 57-64 23708966-5 2013 We also establish that chromatin alterations can themselves enhance KAT5 tyrosine phosphorylation and ATM-dependent signalling, and identify the proto-oncogene c-Abl as a mediator of this modification. Tyrosine 73-81 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 145-165 23691243-8 2013 Activity of the WAVE2 complex binding partner Abl kinase was also increased in WAVE2-KD cells, as assessed by tyrosine phosphorylation of the Abl substrate CrkL. Tyrosine 110-118 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 46-49 23691243-8 2013 Activity of the WAVE2 complex binding partner Abl kinase was also increased in WAVE2-KD cells, as assessed by tyrosine phosphorylation of the Abl substrate CrkL. Tyrosine 110-118 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 142-145 23325923-7 2013 The C-terminal SH3-SH2-SH3 domain and proline-rich region of Vav1 are required for its interaction with c-Abl kinase, and c-Abl kinase probably regulates the activity of Vav1 by direct phosphorylation at Tyr-267 in the DH domain. Tyrosine 204-207 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 104-109 23325923-7 2013 The C-terminal SH3-SH2-SH3 domain and proline-rich region of Vav1 are required for its interaction with c-Abl kinase, and c-Abl kinase probably regulates the activity of Vav1 by direct phosphorylation at Tyr-267 in the DH domain. Tyrosine 204-207 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 122-127 23233201-4 2013 In the present study, we demonstrate that PECAM-1 is tyrosine phospho-rylated in its ITIM motifs in various BCR/ABL-expressing cells including primary leukemia cells. Tyrosine 65-73 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 120-127 23233201-6 2013 We also demonstrate by using a substrate trapping mutant of SHP2 that tyrosine phosphorylated PECAM-1 binds SHP2 and is a major substrate for this tyrosine phosphatase in BCR/ABL-expressing cells. Tyrosine 82-90 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 199-202 22276948-5 2012 Some NRTKs (e.g., Abl) phosphorylate p27 on Tyr 88, which facilitates a second modification on Tyr 74 by another NRTK (e.g., Src). Tyrosine 95-98 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 18-21 22327338-5 2012 By analysis of the adaptor proteins NCK1 and GRB2 mutants we further show that the negative loop on p38 is mediated by c-ABL phosphorylation at tyrosine 105 of the adaptor protein NCK1, while the phosphorylation at tyrosine 209 of GRB2 down-modulates ERK1/2 and JNKs signaling. Tyrosine 144-152 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 119-124 22327338-5 2012 By analysis of the adaptor proteins NCK1 and GRB2 mutants we further show that the negative loop on p38 is mediated by c-ABL phosphorylation at tyrosine 105 of the adaptor protein NCK1, while the phosphorylation at tyrosine 209 of GRB2 down-modulates ERK1/2 and JNKs signaling. Tyrosine 215-223 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 119-124 22810897-3 2012 Our data demonstrated that Abl and Arg were activated downstream of chemokine receptors and mediated the chemokine-induced tyrosine phosphorylation of human enhancer of filamentation 1 (HEF1), an adaptor protein that is required for the activity of the guanosine triphosphatase Rap1, which mediates cell adhesion and migration. Tyrosine 123-131 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 27-30 22276948-5 2012 Some NRTKs (e.g., Abl) phosphorylate p27 on Tyr 88, which facilitates a second modification on Tyr 74 by another NRTK (e.g., Src). Tyrosine 44-47 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 18-21 22199356-0 2012 c-Abl tyrosine kinase regulates serum-induced nuclear export of diacylglycerol kinase alpha by phosphorylation at Tyr-218. Tyrosine 114-117 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 22301057-3 2012 In this study, treatment with endothelin-1 (ET-1) and platelet-derived growth factor (PDGF) increased Abl phosphorylation at Tyr(412) (an indication of Abl activation) in vascular smooth muscle cells. Tyrosine 125-128 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 102-105 22199356-7 2012 Moreover, an in vitro phosphorylation assay using purified mutants of DGKalpha identified Tyr-218 as a site of phosphorylation by c-Abl. Tyrosine 90-93 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 130-135 22199356-9 2012 These results demonstrate that the nucleo-cytoplasmic shuttling of DGKalpha is orchestrated by tyrosine phosphorylation by the Src-activated tyrosine kinase c-Abl and that this phosphorylation is important for regulating the function of cytoplasmic and/or nuclear DGKalpha. Tyrosine 95-103 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 157-162 22232548-4 2012 Recently, we showed that galectin-3 Tyr-107 is phosphorylated by c-Abl; concomitantly, it was also shown that galectin-3 can be cleaved at this site by prostate-specific antigen (PSA), a chymotrypsin-like serine protease, after Tyr-107, resulting in loss of galectin-3 multivalency while preserving its carbohydrate binding activity. Tyrosine 36-39 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 65-70 22238610-4 2012 We found that phosphorylation of PCNA at tyrosine 211 (Y211) enhanced its association with the non-receptor tyrosine kinase c-Abl. Tyrosine 41-49 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 124-129 22558212-6 2012 YAP1 recruits c-Abl, a tyrosine kinase that binds and phosphorylates Nedd4.2 on tyrosine residues, thereby modifying its ubiquitin-ligase activity. Tyrosine 23-31 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 14-19 22252550-6 2012 Furthermore, ABL1 directly phosphorylates NuMA, a binding partner of LGN, on tyrosine 1774. Tyrosine 77-85 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 13-17 21900237-8 2011 Moreover, a phosphomimetic mutation of serine 216 to aspartic acid in Abi1 was sufficient to attenuate Bcr-Abl-induced tyrosine phosphorylation of the WAVE complex and F-actin assembly. Tyrosine 119-127 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 103-110 21602891-0 2011 Phosphorylation of Crk on tyrosine 251 in the RT loop of the SH3C domain promotes Abl kinase transactivation. Tyrosine 26-34 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 82-85 21900237-0 2011 CDK1-mediated phosphorylation of Abi1 attenuates Bcr-Abl-induced F-actin assembly and tyrosine phosphorylation of WAVE complex during mitosis. Tyrosine 86-94 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 49-56 21900237-5 2011 This mitotic inhibition of F-actin assembly is accompanied by an attenuation of Bcr-Abl-induced tyrosine phosphorylation of the WAVE complex. Tyrosine 96-104 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 80-87 22001646-0 2011 Nuclear c-Abl-mediated tyrosine phosphorylation induces chromatin structural changes through histone modifications that include H4K16 hypoacetylation. Tyrosine 23-31 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 8-13 22001646-10 2011 These results suggest that nuclear c-Abl plays an important role in chromatin dynamics through nuclear tyrosine phosphorylation-induced heterochromatic histone modifications. Tyrosine 103-111 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 35-40 21900237-7 2011 The Abi1 phosphorylated on serine 216 displayed greatly reduced tyrosine phosphorylation in the hematopoietic cells transformed by Bcr-Abl. Tyrosine 64-72 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 131-138 21795709-5 2011 Inhibition of PTP1B elicits tyrosine phosphorylation of Bcr-Abl that triggers the degradation of Bcr-Abl through ubiquitination via the lysosomal pathway. Tyrosine 28-36 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 56-63 21769920-5 2011 Furthermore, Abl phosphorylates STH on its single tyrosine residue and STH increases tyrosine phosphorylation by Abl. Tyrosine 50-58 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 13-16 21769920-5 2011 Furthermore, Abl phosphorylates STH on its single tyrosine residue and STH increases tyrosine phosphorylation by Abl. Tyrosine 50-58 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 113-116 21769920-5 2011 Furthermore, Abl phosphorylates STH on its single tyrosine residue and STH increases tyrosine phosphorylation by Abl. Tyrosine 85-93 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 13-16 21769920-5 2011 Furthermore, Abl phosphorylates STH on its single tyrosine residue and STH increases tyrosine phosphorylation by Abl. Tyrosine 85-93 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 113-116 21795709-5 2011 Inhibition of PTP1B elicits tyrosine phosphorylation of Bcr-Abl that triggers the degradation of Bcr-Abl through ubiquitination via the lysosomal pathway. Tyrosine 28-36 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 97-104 21795709-6 2011 The degradation of Bcr-Abl consequently inhibits tyrosine phosphorylation of Bcr-Abl substrates and the downstream production of intracellular reactive oxygen species. Tyrosine 49-57 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 19-26 21795709-6 2011 The degradation of Bcr-Abl consequently inhibits tyrosine phosphorylation of Bcr-Abl substrates and the downstream production of intracellular reactive oxygen species. Tyrosine 49-57 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 77-84 21447799-2 2011 We performed global tyrosine phosphoprofiling by quantitative mass spectrometry of Bcr-Abl-transformed cells in which the activities of the SFKs were perturbed to build a detailed context-dependent network of cancer signaling. Tyrosine 20-28 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 83-90 21715626-6 2011 Oxidative stress induces the c-Abl-dependent tyrosine phosphorylation of MST1 and increases the interaction between MST1 and FOXO3 (Forkhead box O3), thereby activating the MST1-FOXO signaling pathway, leading to cell death in both primary culture neurons and rat hippocampal neurons. Tyrosine 45-53 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 29-34 21715330-5 2011 Incomplete binding-induced folding exposes tyrosine 88 of p27 for phosphorylation by the nonreceptor tyrosine kinase Abl. Tyrosine 43-51 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 117-120 21693657-3 2011 BCR-ABL1-positive Abl1(-/-) leukemia cells were refractory to imatinib as indicated by persistent BCR-ABL1-mediated tyrosine phosphorylation, lack of BCR-ABL1 protein degradation, increased cell survival, and clonogenic activity. Tyrosine 116-124 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 4-8 21440619-4 2011 Tyrosine phosphorylation of PKCdelta was required for PKCdelta binding to c-Abl in the cytoplasm, and inhibition of c-Abl by STI571 or knock-down of c-Abl by RNAi decreased the phosphorylation of PKCdelta. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 74-79 21440619-4 2011 Tyrosine phosphorylation of PKCdelta was required for PKCdelta binding to c-Abl in the cytoplasm, and inhibition of c-Abl by STI571 or knock-down of c-Abl by RNAi decreased the phosphorylation of PKCdelta. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 116-121 21440619-4 2011 Tyrosine phosphorylation of PKCdelta was required for PKCdelta binding to c-Abl in the cytoplasm, and inhibition of c-Abl by STI571 or knock-down of c-Abl by RNAi decreased the phosphorylation of PKCdelta. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 116-121 20717963-0 2011 Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells. Tyrosine 16-24 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-7 21347248-4 2011 METHODOLOGY/PRINCIPAL FINDINGS: By examining the subcellular localization of mutant BCR-ABL proteins under conditions of imatinib and/or leptomycin B treatment to inhibit nuclear export, we have found that mutations of three specific tyrosines (Y232, Y253, Y257, according to ABL-1a numbering) in the kinase domain can inhibit the NLS function of kinase-proficient and kinase-defective BCR-ABL. Tyrosine 234-243 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 84-91 21347248-4 2011 METHODOLOGY/PRINCIPAL FINDINGS: By examining the subcellular localization of mutant BCR-ABL proteins under conditions of imatinib and/or leptomycin B treatment to inhibit nuclear export, we have found that mutations of three specific tyrosines (Y232, Y253, Y257, according to ABL-1a numbering) in the kinase domain can inhibit the NLS function of kinase-proficient and kinase-defective BCR-ABL. Tyrosine 234-243 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 88-91 20861316-5 2010 Conversely, reduced c-Abl expression in EC (siRNA) markedly attenuated S1P-mediated cortical actin formation, reduced the EC modulus of elasticity (assessed by atomic force microscopy), reduced nmMLCK and cortactin tyrosine phosphorylation, and attenuated S1P-mediated barrier enhancement. Tyrosine 215-223 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 20-25 21209200-0 2011 Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson"s disease. Tyrosine 59-67 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 44-49 21209200-2 2011 Here, we show that the stress-signaling non-receptor tyrosine kinase c-Abl links parkin to sporadic forms of PD via tyrosine phosphorylation. Tyrosine 53-61 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 69-74 21209200-6 2011 Our results suggest that tyrosine phosphorylation of parkin by c-Abl is a major post-translational modification that leads to loss of parkin function and disease progression in sporadic PD. Tyrosine 25-33 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 63-68 21199784-4 2011 Abl kinases are activated to reorganize the host actin cytoskeleton and promote the direct tyrosine phosphorylation of viral surface proteins and injected bacterial type-III and type-IV effector molecules. Tyrosine 91-99 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-3 21876762-2 2011 C3G is regulated by tyrosine phosphorylation on Y504, known to be mediated by c-Abl and Src family kinases. Tyrosine 20-28 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 78-83 20937825-9 2010 Further, loss of Abl kinase signaling induces internalization of MT1-MMP from the cell surface, promotes its accumulation in the perinuclear compartment and inhibits MT1-MMP tyrosine phosphorylation. Tyrosine 174-182 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 17-20 20600357-7 2010 Our results demonstrate that tyrosines at positions 79, 107 and 118 can be phosphorylated in vitro and in vivo by c-Abl kinase. Tyrosine 29-38 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 114-119 20600357-8 2010 Tyrosine 107 is the main target of c-Abl. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 35-40 20049867-6 2010 Functional analysis suggested that genistein-regulated protein tyrosine phosphorylation mainly by inhibiting the activity of tyrosine kinase EGFR, PDGFR, insulin receptor, Abl, Fgr, Itk, Fyn and Src. Tyrosine 63-71 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 172-175 20823226-2 2010 Here we show that the nonreceptor tyrosine kinase c-Abl phosphorylates tyrosine 143 of parkin, inhibiting parkin"s ubiquitin E3 ligase activity and protective function. Tyrosine 34-42 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 50-55 20823226-8 2010 Thus, tyrosine phosphorylation of parkin by c-Abl is a major posttranslational modification that inhibits parkin function, possibly contributing to pathogenesis of sporadic PD. Tyrosine 6-14 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 44-49 20563669-4 2010 Overexpression of c-Abl induces tyrosine phosphorylation of Pitx1, either directly or indirectly. Tyrosine 32-40 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 18-23 20111071-5 2010 Dasatinib eradicated Bcr/Abl ALL cells, caused significant apoptosis and eliminated tyrosine phosphorylation on Bcr/Abl, Src, Crkl and Stat-5. Tyrosine 84-92 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 116-119 20598684-2 2010 We previously demonstrated that Abl kinase activity is, itself, regulated by Abi1 subsequent to Abl kinase phosphorylation of Abi1 tyrosine 213 (pY213) [1]. Tyrosine 131-139 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 32-35 20598684-2 2010 We previously demonstrated that Abl kinase activity is, itself, regulated by Abi1 subsequent to Abl kinase phosphorylation of Abi1 tyrosine 213 (pY213) [1]. Tyrosine 131-139 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 96-99 20150913-3 2010 The SH (Src homology)3 domains of c-Abl/Arg bind to a P(80)GPPSGP motif of Gal3, and Tyr79 and Tyr118 are the major tyrosine phosphorylation sites. Tyrosine 116-124 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 34-39 20079431-4 2010 The binding of GADS to Bcr-Abl requires Bcr-Abl tyrosine kinase activity and is sensitive to the Bcr-Abl inhibitor imatinib, while the GADS/Slp-76 and Slp-76/Nck interactions are tyrosine phosphorylation independent. Tyrosine 48-56 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 23-30 20079431-4 2010 The binding of GADS to Bcr-Abl requires Bcr-Abl tyrosine kinase activity and is sensitive to the Bcr-Abl inhibitor imatinib, while the GADS/Slp-76 and Slp-76/Nck interactions are tyrosine phosphorylation independent. Tyrosine 48-56 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 40-47 20079431-4 2010 The binding of GADS to Bcr-Abl requires Bcr-Abl tyrosine kinase activity and is sensitive to the Bcr-Abl inhibitor imatinib, while the GADS/Slp-76 and Slp-76/Nck interactions are tyrosine phosphorylation independent. Tyrosine 48-56 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 40-47 19631450-3 2010 We found that both proteins modulated their reciprocal tyrosine phosphorylation catalyzed by the non-receptor tyrosine kinase c-Abl. Tyrosine 55-63 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 126-131 19818398-3 2010 Recently, biochemical evidence indicated that the c-Abl and Csk kinases were able to phosphorylate the tyrosine 170 (Y170) residue of c-Jun - which lies within the recognition motif of the Itch ubiquitin ligase - and also regulate its stability independent of the JNK phosphorylation sites. Tyrosine 103-111 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 50-55 19833721-3 2009 Silencing caveolin-1 (which blocks CEM formation) and/or c-Abl expression with small interference RNA inhibited hyperoxia-mediated tyrosine phosphorylation and association of dynamin 2 with p47(phox) and ROS production. Tyrosine 131-139 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 57-62 20110615-0 2010 Tau phosphorylated at tyrosine 394 is found in Alzheimer"s disease tangles and can be a product of the Abl-related kinase, Arg. Tyrosine 22-30 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 103-106 19833721-5 2009 Using purified recombinant proteins, we observed that c-Abl tyrosine-phosphorylated dynamin 2, and this phosphorylation increased p47(phox)/dynamin 2 association (change in the dissociation constant (K(d)) from 85.8 to 6.9 nm). Tyrosine 60-68 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 54-59 19423701-9 2009 Tyrosine 52 is further shown to be phosphorylated by c-Abl kinase, and the c-Abl inhibitor STI571 disrupts FAK interaction with RACK1. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 53-58 20110615-4 2010 Recent reports state that tau can be phosphorylated at tyrosine residues by kinases including Fyn, Syk, and c-abl (Abl). Tyrosine 55-63 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 108-113 20110615-4 2010 Recent reports state that tau can be phosphorylated at tyrosine residues by kinases including Fyn, Syk, and c-abl (Abl). Tyrosine 55-63 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 115-118 19702336-6 2009 Translation assays with isolated ribosomes that were phosphorylated in vitro by kinases PKA, PKCdelta, or Abl Tyr showed up to 30% inhibition due to phosphorylation. Tyrosine 110-113 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 106-109 19369965-7 2009 Here, we show that T315I (i) requires autophosphorylation at tyrosine 177 in the BCR-portion to mediate resistance against the inhibition of oligomerization; (ii) restores the capacity to mediate factor-independent growth of loss-of-function mutants due to an increase in or activation of ABL-kinase; (iii) leads to phosphorylation of endogenous BCR, suggesting aberrant substrate activation by BCR/ABL harboring the T315I mutation. Tyrosine 61-69 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 289-292 19369965-7 2009 Here, we show that T315I (i) requires autophosphorylation at tyrosine 177 in the BCR-portion to mediate resistance against the inhibition of oligomerization; (ii) restores the capacity to mediate factor-independent growth of loss-of-function mutants due to an increase in or activation of ABL-kinase; (iii) leads to phosphorylation of endogenous BCR, suggesting aberrant substrate activation by BCR/ABL harboring the T315I mutation. Tyrosine 61-69 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 395-402 19344757-6 2009 We show that pharmacologic inhibition or genetic deletion of cAbl causes a defect in tyrosine phosphorylation of the cytoskeletal adapter CrkII. Tyrosine 85-93 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 61-65 19167484-3 2009 Phosphotyrosine profiling array showed that PTP inhibition following Cr(VI) exposure increased tyrosine phosphorylation of specific proteins, such as FGR and ABL, which are upstream regulators of both Erk and Akt pathways. Tyrosine 7-15 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 158-161 19789182-0 2009 Tyrosine phosphorylation of nuclear-membrane protein emerin by Src, Abl and other kinases. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 68-71 19423701-0 2009 Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for insulin-like growth factor I-mediated regulation of focal adhesion kinase. Tyrosine 28-36 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 43-48 19275932-8 2009 c-Abl phosphorylates three tyrosine residues on PDGFR-beta (Y686, Y934, Y970), while Arg only phosphorylatesY686. Tyrosine 27-35 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 19285032-3 2009 Here, we provide evidence that c-ABL, a tyrosine kinase activated by DNA damage which phosphorylates RAD51 on Tyr-315, works at a previously unrecognized, proximal step to initiate RAD51 assembly. Tyrosine 110-113 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 31-36 19285032-6 2009 We show that phosphorylation on Tyr-315 by c-ABL is required for chromatin association of oligomerization-defective RAD51 mutants, but is insufficient to restore oligomerization. Tyrosine 32-35 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 43-48 19366808-6 2009 Sorafenib also inhibited BCR/ABL-induced tyrosine phosphorylation of its cellular substrates and its autophosphorylation in Ton.B210. Tyrosine 41-49 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 29-32 19135772-2 2009 The purpose of this study was to develop an enzyme-linked immunosorbent (ELISA) method to measure total tyrosine phosphorylation (P-Tyr) in small samples of cells that express BCR-ABL and to compare to more established methods. Tyrosine 104-112 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 176-183 19135772-5 2009 RESULTS: In vitro exposure to TKI resulted in decreases in the level of P-Tyr, in both BCR-ABL-positive cell lines and primary CD34(+) CML samples, which were comparable to the reduction in P-Tyr by flow cytometry and phosphorylation of CrkL by either Western blot or flow cytometry. Tyrosine 74-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 87-94 19077273-12 2008 We show that the inhibition of NMDA receptor currents by Abl kinase is blocked by the inclusion of the Rho kinase inhibitor, Y-27632, and that activation of Abl correlates with an increase in ROCK tyrosine phosphorylation. Tyrosine 197-205 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 57-60 19234221-6 2009 After activated, c-Abl kinase increases the tyrosine phosphorylation of Vav. Tyrosine 44-52 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 17-22 19542604-6 2009 Src family kinases and spleen tyrosine kinase (Syk) have been shown to phosphorylate tyrosine 18 while c-Abl is capable of phosphorylating tyrosine 394. Tyrosine 30-38 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 103-108 19066472-2 2008 While Src and Bcr-Abl were shown to be responsible for tyrosine phosphorylation, no data are available on the dephosphorylation of p27(Kip1) and the phosphatase involved. Tyrosine 55-63 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 14-21 19077273-12 2008 We show that the inhibition of NMDA receptor currents by Abl kinase is blocked by the inclusion of the Rho kinase inhibitor, Y-27632, and that activation of Abl correlates with an increase in ROCK tyrosine phosphorylation. Tyrosine 197-205 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 157-160 18775435-0 2008 Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 96-101 18809728-5 2008 Moreover, we demonstrate that although Abl does not regulate the recruitment of CrkL-C3G into the membrane, it does affect the tyrosine phosphorylation of C3G, which is required for its guanine nucleotide exchange factor activity toward Rap1. Tyrosine 127-135 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 39-42 18701449-8 2008 In response to DNA damage, Yap1 is phosphorylated by c-Abl at the position Tyr-357. Tyrosine 75-78 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 53-58 18632630-3 2008 Treatment of cells that express the mutated receptor variants with the Met inhibitor SU11274 leads, in a mutant-dependent manner, to a reduction of tyrosine phosphorylated levels of Abl and Rad51, impairs radiation-induced nuclear translocation of Rad51, and acts as a radiosensitizer together with the p53 inhibitor pifithrin-alpha by increasing cellular double-strand DNA break levels following exposure to ionizing radiation. Tyrosine 148-156 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 182-185 18235045-5 2008 Lyn also negatively regulates c-Cbl stability, whereas c-Cbl tyrosine phosphorylation is mediated by BCR-ABL. Tyrosine 61-69 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 101-108 18490454-8 2008 In addition, c-Abl modulates Cdk5 activity via phosphorylation of tyrosine 15 in cooperation with cleavage of p35 to p25. Tyrosine 66-74 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 13-18 18285444-3 2008 Tyrosine phosphorylation and kinase activity of PKCdelta are required for PKCdelta binding to Abl in the ER. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 94-97 17686996-7 2007 Ectopic expression of CrkII, a Rac activator that is inactivated by Abl-mediated tyrosine phosphorylation, antagonizes Abl-mediated dorsal membrane localization of RacV12. Tyrosine 81-89 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 68-71 18771174-2 2008 c-Abl is a tyrosine-kinase that takes part in protein phosphorylation on tyrosine. Tyrosine 11-19 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 17804414-2 2007 Critical for the regulation of PKD1 activity in response to oxidative stress are Src- and Abl-mediated tyrosine phosphorylations that eventually lead to protein kinase Cdelta (PKCdelta)-mediated activation of PKD1. Tyrosine 103-111 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 90-93 17587335-0 2007 Anaplasma phagocytophilum AnkA secreted by type IV secretion system is tyrosine phosphorylated by Abl-1 to facilitate infection. Tyrosine 71-79 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 98-103 17686996-7 2007 Ectopic expression of CrkII, a Rac activator that is inactivated by Abl-mediated tyrosine phosphorylation, antagonizes Abl-mediated dorsal membrane localization of RacV12. Tyrosine 81-89 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 119-122 17623672-6 2007 Our results show that the activation of WAVE3 to promote actin remodeling is enhanced by the c-Abl-mediated tyrosine phosphorylation of WAVE3. Tyrosine 108-116 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 93-98 17389688-4 2007 Expression of Bcr-Abl induces tyrosine phosphorylation of Abi1. Tyrosine 30-38 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 14-21 17318191-0 2007 Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. Tyrosine 72-80 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-7 17306540-5 2007 Even though cortactin can be tyrosine phosphorylated by Src-family kinases in vitro [8], we show that Abl and Arg are more adept at binding and phosphorylating cortactin. Tyrosine 29-37 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 102-105 17618275-4 2007 Complex formation results in Abl-mediated phosphorylation of beta-catenin on tyrosine 489, leading to a decrease in its affinity for N-cadherin, loss of N-cadherin function, and targeting of phospho-Y489-beta-catenin to the nucleus. Tyrosine 77-85 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 29-32 17389688-8 2007 More importantly, disruption of the interaction between Bcr-Abl and Abi1 by mutations either in Bcr-Abl or Abi1 not only abolished tyrosine phosphorylation of Abi1 and membrane translocation of Abi1/WAVE2, but also inhibited Bcr-Abl-stimulated actin cytoskeleton remodeling, integrin clustering and cell adhesion to fibronectin. Tyrosine 131-139 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 56-63 17389688-8 2007 More importantly, disruption of the interaction between Bcr-Abl and Abi1 by mutations either in Bcr-Abl or Abi1 not only abolished tyrosine phosphorylation of Abi1 and membrane translocation of Abi1/WAVE2, but also inhibited Bcr-Abl-stimulated actin cytoskeleton remodeling, integrin clustering and cell adhesion to fibronectin. Tyrosine 131-139 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 96-103 17389688-8 2007 More importantly, disruption of the interaction between Bcr-Abl and Abi1 by mutations either in Bcr-Abl or Abi1 not only abolished tyrosine phosphorylation of Abi1 and membrane translocation of Abi1/WAVE2, but also inhibited Bcr-Abl-stimulated actin cytoskeleton remodeling, integrin clustering and cell adhesion to fibronectin. Tyrosine 131-139 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 96-103 17164333-6 2006 Through global phosphoproteome analysis, we identified a unique phosphosubstrate signature associated with each drug-resistant allele, including a shift in phosphorylation of two tyrosines (Tyr253 and Tyr257) in the ATP binding loop (P-loop) of BCR-ABL when Thr315 is Ile or Ala. Tyrosine 179-188 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 245-252 17254966-3 2007 A conserved tyrosine residue (Y88) in the Cdk-binding domain of p27 can be phosphorylated by the Src-family kinase Lyn and the oncogene product BCR-ABL. Tyrosine 12-20 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 144-151 17003374-1 2007 SHP-2 phosphatase forms a stable protein complex with and is heavily tyrosine-phosphorylated by the oncogenic tyrosine kinase Bcr-Abl. Tyrosine 69-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 126-133 17112510-3 2007 The data suggest that c-Abl binds to tyrosine phosphorylated Shb via a concerted effort involving both the c-Abl SH3 and SH2 domains. Tyrosine 37-45 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 22-27 17112510-3 2007 The data suggest that c-Abl binds to tyrosine phosphorylated Shb via a concerted effort involving both the c-Abl SH3 and SH2 domains. Tyrosine 37-45 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 107-112 17126298-0 2007 Tyrosine 311 is phosphorylated by c-Abl and promotes the apoptotic effect of PKCdelta in glioma cells. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 34-39 17126298-2 2007 We found that c-Abl phosphorylated PKCdelta on tyrosine 311 in response to H2O2 and that this phosphorylation contributed to the apoptotic effect of H2O2. Tyrosine 47-55 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 14-19 17126298-6 2007 These results suggest an important role of tyrosine 311 in the apoptotic function of PKCdelta and implicate c-Abl as the kinase that phosphorylates this tyrosine. Tyrosine 153-161 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 108-113 17295370-2 2007 They reduce Bcr-Abl tyrosine phosphorylation and promote apoptosis of the Bcr-Abl-expressing cells. Tyrosine 20-28 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 12-19 17085043-4 2006 A mechanism-based bisubstrate analog strategy has given X-ray crystallographic insights into how several topical PTKs, including the insulin receptor, Abl and epidermal growth factor receptor, interact with tyrosine-containing peptide substrates. Tyrosine 207-215 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 151-154 16678104-2 2006 The present study demonstrates that c-Abl and Arg (abl-related gene) tyrosine kinases associate with and phosphorylate the proteasome PSMA7 (alpha4) subunit at Tyr-153. Tyrosine 160-163 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 36-41 16943190-6 2006 Moreover, we show that activated Abl phosphorylates the EGFR primarily on tyrosine 1173, and that mutation of this site to phenylalanine restores ligand-dependent endocytosis of the EGFR in the presence of activated Abl. Tyrosine 74-82 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 33-36 16702947-0 2006 c-Abl phosphorylates Hdm2 at tyrosine 276 in response to DNA damage and regulates interaction with ARF. Tyrosine 29-37 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 16702947-3 2006 As part of this mechanism ATM itself, and the ATM-activated protein tyrosine kinase, c-Abl, inhibit Hdm2 function through phosphorylation of serine 395 and tyrosine 394 (Y394), respectively. Tyrosine 68-76 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 85-90 16702947-4 2006 In the present study, we have identified a novel target of c-Abl in the Hdm2 protein, tyrosine 276 (Y276). Tyrosine 86-94 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 59-64 16899465-6 2006 Furthermore, Abl phosphorylates WAVE2 on tyrosine 150, and WAVE2-deficient cells rescued with a Y150F mutant fail to regain their ability to ruffle and form microspikes, unlike cells rescued with wild-type WAVE2. Tyrosine 41-49 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 13-16 16899465-7 2006 Together, these data show that c-Abl activates WAVE2 via tyrosine phosphorylation to promote actin remodeling in vivo and that Abi-1 forms the crucial link between these two factors. Tyrosine 57-65 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 31-36 16912036-6 2006 Substitution of the SH3-SH2 tyrosine phosphorylation sites with phenylalanine substantially reduced Bcr-Abl-mediated transformation of TF-1 myeloid cells to cytokine independence. Tyrosine 28-36 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 100-107 16912036-7 2006 The positions of these tyrosines in the crystal structure of the c-Abl core and the transformation defect of the corresponding Bcr-Abl mutants together suggest that phosphorylation of the SH3-SH2 region by Src family kinases impacts Bcr-Abl protein conformation and signaling. Tyrosine 23-32 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 65-70 16912036-7 2006 The positions of these tyrosines in the crystal structure of the c-Abl core and the transformation defect of the corresponding Bcr-Abl mutants together suggest that phosphorylation of the SH3-SH2 region by Src family kinases impacts Bcr-Abl protein conformation and signaling. Tyrosine 23-32 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 127-134 16912036-7 2006 The positions of these tyrosines in the crystal structure of the c-Abl core and the transformation defect of the corresponding Bcr-Abl mutants together suggest that phosphorylation of the SH3-SH2 region by Src family kinases impacts Bcr-Abl protein conformation and signaling. Tyrosine 23-32 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 233-240 16670264-5 2006 Northern and Western blotting plus immunocytochemical analysis confirmed CCN3 expression is decreased and is tyrosine-phosphorylated in BCR-ABL kinase active FDCP-Mix cells. Tyrosine 109-117 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 136-143 16888623-4 2006 The results demonstrate that c-Abl phosphorylates MUC1 on Tyr-60 and forms a complex with MUC1 by binding of the c-Abl SH2 domain to the pTyr-60 site. Tyrosine 58-61 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 29-34 16888623-4 2006 The results demonstrate that c-Abl phosphorylates MUC1 on Tyr-60 and forms a complex with MUC1 by binding of the c-Abl SH2 domain to the pTyr-60 site. Tyrosine 58-61 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 113-118 16858728-4 2006 By metabolically labeling proteins with light or heavy tyrosine, we are able to quantify the change in phosphorylation of BCR-ABL kinase and its substrates in response to drug treatment in human CML cells. Tyrosine 55-63 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 122-129 16858728-5 2006 In this study, we observed that BCR-ABL kinase is phosphorylated at tyrosines 393 and 644, and that SH2-domain containing inositol phosphatase (SHIP)-2 and downstream of kinase (Dok)-2 are phosphorylated at tyrosine 1135 and 299, respectively. Tyrosine 68-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 32-39 16858728-5 2006 In this study, we observed that BCR-ABL kinase is phosphorylated at tyrosines 393 and 644, and that SH2-domain containing inositol phosphatase (SHIP)-2 and downstream of kinase (Dok)-2 are phosphorylated at tyrosine 1135 and 299, respectively. Tyrosine 68-76 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 32-39 16888623-6 2006 We also show that expression of MUC1 with a mutation at Tyr-60 (i) disrupts the interaction between MUC1 and c-Abl, (ii) relieves the MUC1-induced block of c-Abl phosphorylation on Thr-735 and binding to 14-3-3, and (iii) attenuates the MUC1 antiapoptotic function. Tyrosine 56-59 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 109-114 16888623-6 2006 We also show that expression of MUC1 with a mutation at Tyr-60 (i) disrupts the interaction between MUC1 and c-Abl, (ii) relieves the MUC1-induced block of c-Abl phosphorylation on Thr-735 and binding to 14-3-3, and (iii) attenuates the MUC1 antiapoptotic function. Tyrosine 56-59 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 156-161 15893754-6 2005 The phosphorylation sites of BCAP by c-Abl were mapped to five tyrosine residues in the C-terminal region that are well conserved in mammals. Tyrosine 63-71 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 37-42 16267043-2 2006 Activated Abl phosphorylates tyrosine 221 of c-CrkII (Crk; Crk-Y221-P), which prevents Crk from binding to the docking protein p130(CAS) (CAS). Tyrosine 29-37 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 10-13 16732964-4 2006 Expression of bcr-abl mRNA was detected by RT-PCR and tyrosine phosphorylation of BCR-ABL fusion protein by Western blot. Tyrosine 54-62 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 82-89 16732964-7 2006 In CML MNC after imatinib treatment and in K562 cells, expression of hMSH2, hMSH3 and hMLH1 mRNA was enhanced while tyrosine phosphorylation of BCR-ABL fusion protein decreased. Tyrosine 116-124 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 144-151 16158058-3 2006 We show that Rb is constitutively phosphorylated at tyrosine in Abl-dependent tumor cells, and that Abl phosphorylates Rb specifically at Y805 within the C-terminal domain of the molecule. Tyrosine 52-60 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 64-67 16158058-3 2006 We show that Rb is constitutively phosphorylated at tyrosine in Abl-dependent tumor cells, and that Abl phosphorylates Rb specifically at Y805 within the C-terminal domain of the molecule. Tyrosine 52-60 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 100-103 16158058-6 2006 Thus, our findings suggest that Abl-catalysed tyrosine phosphorylation of Rb is necessary for survival of Abl-dependent human tumor cells, and raises the possibility that this phosphorylated Rb can be a molecular target for cancer therapy aimed at inducing apoptosis of Abl-dependent tumor cells, such as Bcr/Abl-positive CML. Tyrosine 46-54 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 32-35 16158058-6 2006 Thus, our findings suggest that Abl-catalysed tyrosine phosphorylation of Rb is necessary for survival of Abl-dependent human tumor cells, and raises the possibility that this phosphorylated Rb can be a molecular target for cancer therapy aimed at inducing apoptosis of Abl-dependent tumor cells, such as Bcr/Abl-positive CML. Tyrosine 46-54 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 106-109 16158058-6 2006 Thus, our findings suggest that Abl-catalysed tyrosine phosphorylation of Rb is necessary for survival of Abl-dependent human tumor cells, and raises the possibility that this phosphorylated Rb can be a molecular target for cancer therapy aimed at inducing apoptosis of Abl-dependent tumor cells, such as Bcr/Abl-positive CML. Tyrosine 46-54 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 106-109 16158058-6 2006 Thus, our findings suggest that Abl-catalysed tyrosine phosphorylation of Rb is necessary for survival of Abl-dependent human tumor cells, and raises the possibility that this phosphorylated Rb can be a molecular target for cancer therapy aimed at inducing apoptosis of Abl-dependent tumor cells, such as Bcr/Abl-positive CML. Tyrosine 46-54 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 106-109 16286457-4 2006 Tyr-161 shares similarity to the consensus sequence for phosphorylation by the nonreceptor tyrosine kinases Abl and Arg. Tyrosine 0-3 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 108-111 16286457-6 2006 Moreover, treatment of neurons with two structurally distinct and highly selective Abl inhibitors, PD173955 and Gleevec, blocks HK-induced phosphorylation of IkappaB-beta at Tyr-161 and induces neuronal apoptosis. Tyrosine 174-177 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 83-86 16157305-2 2005 Imatinib mesylate inhibits Bcr-Abl tyrosine kinase, resulting in a blockage of tyrosine phosphorylation in its downstream pathways. Tyrosine 35-43 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 27-34 16639034-5 2006 Therefore, tyrosine phosphorylation-dependent signaling involving receptor tyrosine kinases, mitogen-activated protein kinases, Abl, Src, and Pyk2 is known to be initiated or amplified by reactive oxidants. Tyrosine 11-19 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 128-131 16484222-5 2006 In contrast, we present evidence that RET/PTC3 acts on Erk8 through Tyr(981)-mediated activation of c-Abl. Tyrosine 68-71 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 100-105 16014719-0 2005 Tyrosine 394 is phosphorylated in Alzheimer"s paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 96-101 16014719-7 2005 Tyrosine phosphorylation of tau was inhibited by PP2 (4-amino-5-(4-chlorophenyl-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), which is known to inhibit Src-family kinases and c-Abl. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 168-173 16014719-8 2005 Cotransfection of tau and kinases showed that Tyr-18 was the major site for Fyn phosphorylation, but Tyr-394 was the main residue for Abl. Tyrosine 101-104 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 134-137 16014719-11 2005 These results show that phosphorylation of tau on Tyr-394 is a physiological event that is potentially part of a signal relay and suggest that Abl could have a pathogenic role in Alzheimer"s disease. Tyrosine 50-53 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 143-146 15942030-7 2005 C-Abl tyrosine phosphorylates OGG1 in vitro; however, this phosphorylation event does not affect OGG1 8-oxoG/C incision activity. Tyrosine 6-14 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 15850559-4 2005 c-Abl was associated with RNA polymerase II (RNAP II) in vivo and augmented the tyrosine phosphorylation of the largest subunit of RNAP II. Tyrosine 80-88 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 15850559-6 2005 The combined results suggest that c-Abl plays an important role in the transcriptional regulation of c-fos gene and the tyrosine phosphorylation of the largest subunit of RNAP II by c-Abl is involved in the regulating process. Tyrosine 120-128 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 182-187 15659545-6 2005 At least two of the ArgBP2/nArgBP2 binding partners, synaptojanin 2B and WAVE2, undergo ubiquitination and Abl-dependent tyrosine phosphorylation. Tyrosine 121-129 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 107-110 15681433-6 2005 Further analysis revealed that Shc is required for v-Abl-mediated Raf tyrosine 340 and 341 phosphorylation, an event associated with Erk phosphorylation. Tyrosine 70-78 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 51-56 15890005-6 2005 c-Abl and Arg nonreceptor protein tyrosine kinases associate with catalase in cells treated with H(2)O(2) by mechanisms involving the SH3 domains of the kinases and the Pro(293)PheAsnPro motif of catalase and activate catalase by phosphorylating it on Tyr(231) and Tyr(386). Tyrosine 252-255 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 15890005-6 2005 c-Abl and Arg nonreceptor protein tyrosine kinases associate with catalase in cells treated with H(2)O(2) by mechanisms involving the SH3 domains of the kinases and the Pro(293)PheAsnPro motif of catalase and activate catalase by phosphorylating it on Tyr(231) and Tyr(386). Tyrosine 265-268 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 15657060-4 2005 We show that c-Abl phosphorylates caspase-9 on Tyr-153 in vitro and in cells treated with DNA damaging agents. Tyrosine 47-50 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 13-18 15721630-6 2005 Furthermore, ex vivo treatment of leukemic cells with imatinib significantly reduced tyrosine phosphorylation of CrkL, a target of the BCR/ABL kinase. Tyrosine 85-93 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 135-142 15468123-1 2004 BACKGROUND: Constitutive tyrosine phosphorylation derived from Bcr-Abl kinase activity is the major characteristic of Bcr-Abl positive cells. Tyrosine 25-33 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 63-70 15604256-3 2004 PKD2 was found to be the major isoform of the PKD family expressed in chronic myeloid leukemia cells and is tyrosine phosphorylated by Bcr-Abl in its pleckstrin homology domain. Tyrosine 108-116 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 135-142 15604256-5 2004 Furthermore, our data show that Bcr-Abl-induced activation of the nuclear factor kappaB cascade in LAMA84 cells is largely mediated by tyrosine-phosphorylated PKD2. Tyrosine 135-143 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 32-39 15604256-7 2004 Targeting PKD2 tyrosine phosphorylation, not its kinase activity, could be a novel therapeutic approach for the treatment of Bcr-Abl(+) myeloid leukemia. Tyrosine 15-23 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 125-132 15468123-1 2004 BACKGROUND: Constitutive tyrosine phosphorylation derived from Bcr-Abl kinase activity is the major characteristic of Bcr-Abl positive cells. Tyrosine 25-33 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 118-125 15468123-5 2004 Tyrosine phosphorylation was inhibited by imatinib in a dose-dependent manner, but not modified by other inhibitors demonstrating that the staining detected is specific to Bcr-Abl phosphorylation. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 172-179 15256422-6 2004 AP23464 ablates Bcr-Abl tyrosine phosphorylation, blocks cell cycle progression, and promotes apoptosis of Bcr-Abl-expressing cells. Tyrosine 24-32 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 16-23 15194504-4 2004 When expressed in COS7 cells, the BCR/ABL construct with either E255K or T315I exhibited not only the resistance to imatinib but also the increase in activity to induce autophosphorylation as well as tyrosine phosphorylation of various cellular proteins, which included STAT5. Tyrosine 200-208 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 34-41 15175272-3 2004 We show that YT521-B is tyrosine phosphorylated by c-Abl in the nucleus. Tyrosine 24-32 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 51-56 15313630-11 2004 Furthermore, the mutation by Tyr of two proline residues in APP-RP1, which are essential for the binding of some linear peptides to Abl-SH3, demonstrates the effectiveness of the scaffold in enhancing the variability in the design of high-affinity and high-specificity ligands for any SH3 domain. Tyrosine 29-32 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 132-135 15143164-2 2004 Here, we demonstrate direct binding of Grb2 to the Tel-Abl (ETV6-Abl) fusion protein, the product of complex (9;12) chromosomal translocations in human leukemia, via tyrosine 314 encoded by TEL exon 5. Tyrosine 166-174 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 55-58 15031292-6 2004 Here, we show that active c-Abl stimulates APP/Fe65-mediated gene transcription and that this effect is mediated by phosphorylation of Fe65 on tyrosine 547 within its second PTB domain. Tyrosine 143-151 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 26-31 15039778-0 2004 Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation. Tyrosine 14-22 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-3 15024053-7 2004 Tyrosine phosphorylation in the PH domain at Tyr463, mediated by the Src-Abl pathway, which in turn facilitates the phosphorylation of Ser738/Ser742 in the activation loop, mediated by the Src-PKCdelta pathway. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 73-76 15171550-7 2004 In cell-based assays of ABL tyrosine phosphorylation, the ability of two kinds of novel, structurally diverse, lead compounds to inhibit ABL kinase activity was observed. Tyrosine 28-36 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 24-27 15171550-7 2004 In cell-based assays of ABL tyrosine phosphorylation, the ability of two kinds of novel, structurally diverse, lead compounds to inhibit ABL kinase activity was observed. Tyrosine 28-36 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 137-140 15039778-5 2004 We show that Sos-1, a dual guanine nucleotide-exchange factor (GEF), is phosphorylated on tyrosine, after activation of RTKs, in an Abl-dependent manner. Tyrosine 90-98 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 132-135 15039778-6 2004 Sos-1 and Abl interact in vivo, and Abl-induced tyrosine phosphorylation of Sos-1 is sufficient to elicit its Rac-GEF activity in vitro. Tyrosine 48-56 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 36-39 14725908-1 2004 Cbl is one of the major tyrosine-phosphorylated proteins in Bcr-Abl-expressing cells. Tyrosine 24-32 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 60-67 14725908-2 2004 A direct association between the SH2 domain of Bcr-Abl and tyrosine-phosphorylated Cbl has been demonstrated. Tyrosine 59-67 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 47-54 14725908-6 2004 Bcr-Abl did, however, associate with Grb2, an adaptor protein that binds tyrosine 177 of Bcr-Abl. Tyrosine 73-81 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-7 14725908-6 2004 Bcr-Abl did, however, associate with Grb2, an adaptor protein that binds tyrosine 177 of Bcr-Abl. Tyrosine 73-81 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 89-96 14725908-10 2004 In cells expressing Bcr-Abl with a mutation in the Grb2 binding site, binding of Cbl to Bcr-Abl was significantly reduced, but Cbl tyrosine phosphorylation was maintained. Tyrosine 131-139 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 20-27 14725908-14 2004 Following this initial interaction, Cbl can then become tyrosine phosphorylated and interact with the SH2 domain of Bcr-Abl, further stabilizing the complex. Tyrosine 56-64 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 116-123 14654952-7 2004 Site-directed mutagenesis of Y881 aa within the RAFTK sequence abolished the binding of RAFTK to c-Abl, indicating that the tyrosine residue 881 of RAFTK is the c-Abl binding site within the RAFTK molecule. Tyrosine 124-132 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 97-102 14654952-7 2004 Site-directed mutagenesis of Y881 aa within the RAFTK sequence abolished the binding of RAFTK to c-Abl, indicating that the tyrosine residue 881 of RAFTK is the c-Abl binding site within the RAFTK molecule. Tyrosine 124-132 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 161-166 14604282-4 2003 Imatinib mesylate remarkably reduced tyrosine phosphorylation of Bcr-Abl, Cbl, and Crkl in a time-dependent manner, and their complex formation also was affected. Tyrosine 37-45 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 65-72 12893824-4 2003 GPx1 also functions as a substrate for c-Abl- and Arg-mediated phosphorylation on Tyr-96. Tyrosine 82-85 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 39-44 14552760-7 2003 Two promising compounds showed inhibition in further ABL tyrosine phosphorylation assay. Tyrosine 57-65 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 53-56 14527680-1 2003 The myristoylated N-terminal latching to the C-terminal lobe of c-Abl was recently demonstrated to be an important regulatory element for the kinase, playing a role similar to that of the tyrosine-phosphorylated C-terminal tail of c-Src. Tyrosine 188-196 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 64-69 12824179-3 2003 Under these conditions p73 is tyrosine-phosphorylated by c-Abl, a prerequisite modification for p73 to elicit cell death in fibroblasts. Tyrosine 30-38 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 57-62 12824179-8 2003 Under these conditions p73 alpha but not p53 is specifically tyrosine-phosphorylated by c-Abl. Tyrosine 61-69 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 88-93 12777393-5 2003 Interaction of Dok-R with c-Abl also results in an increase in c-Abl tyrosine phosphorylation and kinase activity. Tyrosine 69-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 26-31 12955086-3 2003 c-Abl phosphorylates the cytoskeleton-associated adaptor protein, Crk, at tyrosine 221, causing disassociation of Crk from the Crk-associated substrate (CAS) and disassembly of Crk/CAS complexes. Tyrosine 74-82 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 12777393-5 2003 Interaction of Dok-R with c-Abl also results in an increase in c-Abl tyrosine phosphorylation and kinase activity. Tyrosine 69-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 63-68 12833568-5 2003 High-resolution affinity panning coupled with mass spectrometric readout allows for quick identification of Trp as the preferred fourth residue in the decapeptide ligand APTWSPPPPP, which binds to Abl SH3 four times stronger than does the decapeptide containing Tyr or Phe in the fourth position. Tyrosine 262-265 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 197-200 12879454-0 2003 Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity. Tyrosine 44-52 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 84-87 12938259-3 2003 Imatinib mesylate binds to the amino acids of the BCR-ABL tyrosine kinase ATP binding site and stabilizes the inactive, non-ATP-binding form of BCR-ABL, thereby preventing tyrosine autophosphorylation, and in turn, phosphorylation of its substrates. Tyrosine 58-66 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 50-57 12748290-2 2003 Following the breakdown of inhibitory intramolecular interactions, Abl activation requires phosphorylation on several tyrosine residues, including a tyrosine in its activation loop. Tyrosine 118-126 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 67-70 12748290-2 2003 Following the breakdown of inhibitory intramolecular interactions, Abl activation requires phosphorylation on several tyrosine residues, including a tyrosine in its activation loop. Tyrosine 149-157 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 67-70 12637538-6 2003 Mutational analysis revealed three tyrosine phosphorylation sites (Tyr(432), Tyr(463), and Tyr(502)), which are regulated by the Src-Abl pathway, and phosphorylation of only one of these (Tyr(463)) leads to PKD activation. Tyrosine 77-80 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 133-136 12637538-7 2003 By using a phospho-specific antibody, we show that Abl directly phosphorylates PKD at Tyr(463) in vitro, and in cells phosphorylation of this site is sufficient to mediate full activation of PKD. Tyrosine 86-89 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 51-54 12833568-6 2003 This finding is in contrast to several reports that Tyr is the only residue selected from phage displayed peptide libraries that interacts with the specificity pocket of Abl SH3. Tyrosine 52-55 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 170-173 12446442-2 2003 Cotreatment with SAHA and imatinib (Gleevec) caused more down-regulation of the levels and auto-tyrosine phosphorylation of Bcr-Abl and apoptosis of these cell types, as compared with treatment with either agent alone (P <.05). Tyrosine 96-104 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 124-131 12810679-6 2003 Consequence to the phosphorylation is a marked increase of the association between c-Abl and p73 via the binding of tyrosine-phosphorylated p73 to the c-Abl Src homology 2 (SH2) domain. Tyrosine 116-124 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 83-88 12810679-6 2003 Consequence to the phosphorylation is a marked increase of the association between c-Abl and p73 via the binding of tyrosine-phosphorylated p73 to the c-Abl Src homology 2 (SH2) domain. Tyrosine 116-124 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 151-156 12672821-0 2003 Abl interactor 1 promotes tyrosine 296 phosphorylation of mammalian enabled (Mena) by c-Abl kinase. Tyrosine 26-34 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 86-91 12672821-7 2003 Importantly, Abi-1 dramatically promoted c-Abl-mediated tyrosine phosphorylation of Mena but not other substrates such as c-Cbl. Tyrosine 56-64 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 41-46 12637538-6 2003 Mutational analysis revealed three tyrosine phosphorylation sites (Tyr(432), Tyr(463), and Tyr(502)), which are regulated by the Src-Abl pathway, and phosphorylation of only one of these (Tyr(463)) leads to PKD activation. Tyrosine 35-43 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 133-136 12637538-6 2003 Mutational analysis revealed three tyrosine phosphorylation sites (Tyr(432), Tyr(463), and Tyr(502)), which are regulated by the Src-Abl pathway, and phosphorylation of only one of these (Tyr(463)) leads to PKD activation. Tyrosine 67-70 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 133-136 12637538-6 2003 Mutational analysis revealed three tyrosine phosphorylation sites (Tyr(432), Tyr(463), and Tyr(502)), which are regulated by the Src-Abl pathway, and phosphorylation of only one of these (Tyr(463)) leads to PKD activation. Tyrosine 77-80 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 133-136 12637538-6 2003 Mutational analysis revealed three tyrosine phosphorylation sites (Tyr(432), Tyr(463), and Tyr(502)), which are regulated by the Src-Abl pathway, and phosphorylation of only one of these (Tyr(463)) leads to PKD activation. Tyrosine 77-80 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 133-136 12644574-2 2003 The tyrosine-phosphorylated fraction of the p185 form of Bcr/Abl was isolated by immunoprecipitation with an anti-phosphotyrosine antibody and SDS-PAGE. Tyrosine 4-12 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 57-64 12531427-2 2003 Tyrosine 14 is a consensus Abl phosphorylation site suggesting that caveolin-1 may be an Abl substrate. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 27-30 12531427-2 2003 Tyrosine 14 is a consensus Abl phosphorylation site suggesting that caveolin-1 may be an Abl substrate. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 89-92 12531427-6 2003 Oxidative stress-induced tyrosine phosphorylation of caveolin-1 occurs only at the Abl site, tyrosine 14. Tyrosine 25-33 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 83-86 12531427-6 2003 Oxidative stress-induced tyrosine phosphorylation of caveolin-1 occurs only at the Abl site, tyrosine 14. Tyrosine 93-101 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 83-86 12654250-7 2003 This mechanism offers an explanation for the observed cellular activation of c-Abl by tyrosine-phosphorylated proteins, the intracellular mobility of c-Abl, and it provides new insights into the mechanism of action of STI-571. Tyrosine 86-94 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 77-82 12522270-4 2003 We used this methodology to follow changes in tyrosine phosphorylation patterns that occur over time during either the activation of human T cells or the inhibition of the oncogenic BCR-ABL fusion product in chronic myelogenous leukemia cells in response to treatment with STI571 (Gleevec). Tyrosine 46-54 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 182-189 12370803-1 2002 We have previously shown that the Jak2 tyrosine kinase is activated in Bcr-Abl positive cell lines and blood cells from CML blast crisis patients by tyrosine phosphorylation. Tyrosine 39-47 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 71-78 12379650-4 2002 We show here that c-Abl tyrosine kinase associates with and phosphorylates Rad52 on tyrosine 104. Tyrosine 24-32 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 18-23 12476302-3 2002 Another consequence of this Bcr-Abl fusion is the extensive autophosphorylation of the cis Bcr protein sequences on tyrosine residues. Tyrosine 116-124 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 28-35 12476302-4 2002 This review will summarize the effects of Bcr-Abl autophosphorylation on tyrosines as they relate to the oncogenic activity of Bcr-Abl, and as a means to inactivate the serine/threonine kinase activity of the Bcr protein. Tyrosine 73-82 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 42-49 12476302-4 2002 This review will summarize the effects of Bcr-Abl autophosphorylation on tyrosines as they relate to the oncogenic activity of Bcr-Abl, and as a means to inactivate the serine/threonine kinase activity of the Bcr protein. Tyrosine 73-82 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 127-134 12445832-4 2002 In this report we describe for the first time that c-Abl and Btk physically interact and that c-Abl can phosphorylate tyrosine 223 in the SH3 domain of Btk. Tyrosine 118-126 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 51-56 12445832-4 2002 In this report we describe for the first time that c-Abl and Btk physically interact and that c-Abl can phosphorylate tyrosine 223 in the SH3 domain of Btk. Tyrosine 118-126 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 94-99 12149456-0 2002 Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Tyrosine 95-98 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 110-113 12167702-3 2002 Interestingly, the association of c-Abl with IkappaBalpha, which is detectable in the form of nonphosphorylated proteins, is remarkably enhanced by an inducible binding of tyrosine-phosphorylated IkappaBalpha to the c-Abl SH2 domain. Tyrosine 172-180 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 34-39 12167702-3 2002 Interestingly, the association of c-Abl with IkappaBalpha, which is detectable in the form of nonphosphorylated proteins, is remarkably enhanced by an inducible binding of tyrosine-phosphorylated IkappaBalpha to the c-Abl SH2 domain. Tyrosine 172-180 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 216-221 12167702-4 2002 In contrast to the serine 32/34 phosphorylation that triggers ubiquitination and degradation of IkappaBalpha, c-Abl-mediated phosphorylation at tyrosine 305 is associated with an increase of the IkappaBalpha protein stability. Tyrosine 144-152 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 110-115 12149456-3 2002 Here we identify mutations of Tyr-253 in the nucleotide-binding (P) loop of the Abl kinase domain to Phe or His in patients with advanced CML and acquired STI-571 resistance. Tyrosine 30-33 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 80-83 12149456-5 2002 The response of Abl proteins to STI-571 was influenced by the regulatory state of the kinase and by tyrosine phosphorylation. Tyrosine 100-108 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 16-19 12149456-6 2002 The sensitivity of purified c-Abl to STI-571 was increased by a dysregulating mutation (P112L) in the Src homology 3 domain of Abl but decreased by phosphorylation at the regulatory Tyr-393. Tyrosine 182-185 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 28-33 12149456-6 2002 The sensitivity of purified c-Abl to STI-571 was increased by a dysregulating mutation (P112L) in the Src homology 3 domain of Abl but decreased by phosphorylation at the regulatory Tyr-393. Tyrosine 182-185 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 30-33 12154026-9 2002 PD173955 has an IC(50) of 1-2 nM in kinase inhibition assays of Bcr-Abl, and in cellular growth assays it inhibits Bcr-Abl-dependent substrate tyrosine phosphorylation. Tyrosine 143-151 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 115-122 11790798-7 2002 Furthermore, we show tyrosine phosphorylation of Vav by Bcr-Abl. Tyrosine 21-29 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 56-63 12124177-3 2002 The autophosphorylation site tyrosine 177 binds the adaptor Grb2 and helps determine the lineage and severity of BCR/ABL disease: Tyr177 mutation (BCR/ABL-Y177F) dramatically impairs myeloid leukemogenesis, while diminishing lymphoid leukemogenesis. Tyrosine 29-37 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 113-120 12124177-6 2002 Compared to BCR/ABL-expressing Ba/F3 cells, BCR/ABL-Y177F cells exhibit markedly reduced Gab2 tyrosine phosphorylation and association of phosphatidylinositol-3 kinase (PI3K) and Shp2 with Gab2 and BCR/ABL, and decreased PI3K/Akt and Ras/Erk activation, cell proliferation, and spontaneous migration. Tyrosine 94-102 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 44-51 11971963-5 2002 c-Abl phosphorylates the Rad9 Bcl-2 homology 3 domain (Tyr-28) in vitro and in cells exposed to DNA-damaging agents. Tyrosine 55-58 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 12110584-0 2002 Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 36-41 11494128-8 2001 A third interaction between Abl and EphB2 is probably mediated by an intermediary protein because it requires tyrosine phosphorylation of EphB2, but not the binding sites for the Abl SH2 domain. Tyrosine 110-118 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 28-31 11781820-3 2001 Here we report tyrosine phosphorylation of endogenous c-Abl and a concomitant increase in catalytic activity. Tyrosine 15-23 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 54-59 11781820-9 2001 These mutations resulted in tyrosine phosphorylation and activation of c-Abl, as if relieving c-Abl from inhibition. Tyrosine 28-36 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 94-99 11684015-5 2001 Phosphorylation of the RAD51 Tyr-315 residue by BCR/ABL appears essential for enhanced DSB repair and drug resistance. Tyrosine 29-32 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 52-55 11726515-0 2001 Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 36-43 11726515-2 2001 We found that Grb2 was tyrosine-phosphorylated in cells expressing BCR/ABL and in A431 cells stimulated with epidermal growth factor (EGF). Tyrosine 23-31 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 67-74 11698276-6 2001 Here, it is shown that JAK2 is constitutively tyrosine phosphorylated in cultured and primary erythroid cells expressing BCR-ABL. Tyrosine 46-54 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 121-128 11593427-0 2001 Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Tyrosine 20-28 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 52-55 11593427-1 2001 We have previously reported that the Jak2 tyrosine kinase but not Jak1 is tyrosine phosphorylated in the absence of IL-3 in Bcr-Abl positive M3.16 cells, which are rendered IL-3 independent by BCR-ABL gene expression. Tyrosine 42-50 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 124-131 11593427-1 2001 We have previously reported that the Jak2 tyrosine kinase but not Jak1 is tyrosine phosphorylated in the absence of IL-3 in Bcr-Abl positive M3.16 cells, which are rendered IL-3 independent by BCR-ABL gene expression. Tyrosine 42-50 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 193-200 11593427-3 2001 Our results indicate that Jak2 became tyrosine-phosphorylated in a number of cell lines expressing Bcr-Abl, when maintained in medium lacking IL-3, whereas Bcr-Abl negative cells lacked Jak2 tyrosine phosphorylation. Tyrosine 38-46 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 99-106 11593427-5 2001 Moreover, tyrosine phosphorylation of Jak2 by Bcr-Abl was inhibited by the Abl tyrosine kinase inhibitor, STI 571, in a dose-dependent manner. Tyrosine 10-18 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 46-53 11593427-5 2001 Moreover, tyrosine phosphorylation of Jak2 by Bcr-Abl was inhibited by the Abl tyrosine kinase inhibitor, STI 571, in a dose-dependent manner. Tyrosine 10-18 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 50-53 11494128-6 2001 The SH2 domains of Abl and Arg bind to tyrosine-phosphorylated motifs in the juxtamembrane region of EphB2. Tyrosine 39-47 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 19-22 11494128-10 2001 Activated EphB2 causes tyrosine phosphorylation of Abl and Arg, and vice versa. Tyrosine 23-31 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 51-54 11494134-9 2001 Studies with Nck mutants suggested that the Nck SH2 domain is responsible for inhibiting the activity of Abl toward both Cbl and Nck itself, most likely by competing with the Abl SH2 for tyrosine-phosphorylated binding sites. Tyrosine 187-195 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 105-108 11494134-9 2001 Studies with Nck mutants suggested that the Nck SH2 domain is responsible for inhibiting the activity of Abl toward both Cbl and Nck itself, most likely by competing with the Abl SH2 for tyrosine-phosphorylated binding sites. Tyrosine 187-195 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 175-178 11279131-0 2001 The beta-amyloid precursor protein APP is tyrosine-phosphorylated in cells expressing a constitutively active form of the Abl protoncogene. Tyrosine 42-50 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 122-125 11279131-6 2001 Furthermore, in cells expressing the active form of Abl, APP is tyrosine-phosphorylated. Tyrosine 64-72 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 52-55 11279131-8 2001 Co-immunoprecipitation experiments demonstrate that active Abl and tyrosine-phosphorylated APP also form a stable complex, which could result from the interaction of the pYENP motif of the APP cytodomain with the SH2 domain of Abl. Tyrosine 67-75 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 227-230 11080615-1 2000 c-Abl preferentially phosphorylates peptide substrates that contain proline at the P+3 site (relative to the phosphorylated tyrosine). Tyrosine 124-132 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 11342454-8 2001 All this is accompanied by inhibition of c-Abl tyrosine phosphorylation and retardation of the retinoid-dependent degradation of PML-RARalpha and RARalpha. Tyrosine 47-55 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 41-46 11339833-0 2001 Caveolin-1 and a 29-kDa caveolin-associated protein are phosphorylated on tyrosine in cells expressing a temperature-sensitive v-Abl kinase. Tyrosine 74-82 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 127-132 11339833-4 2001 We found that caveolin-1 is also phosphorylated on tyrosine in v-Abl-transformed cells. Tyrosine 51-59 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 63-68 11339833-8 2001 Caveolin-1 is phosphorylated at tyrosine 14 in v-Abl-expressing cells as has been observed previously in v-Src-expressing cells. Tyrosine 32-40 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 47-52 11380621-5 2001 The activation of c-Abl by c-Crk is negatively regulated by phosphorylation of the tyrosine 221 of c-Crk. Tyrosine 83-91 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 18-23 11121037-5 2000 Cotransfection of c-Abl and gamma-PAK elicits phosphorylation of gamma-PAK on tyrosine and down-regulation of gamma-PAK activity, promoting accumulation of inactive gamma-PAK. Tyrosine 78-86 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 18-23 11376433-6 2001 Using these antibodies, we established/confirmed the in vivo phosphorylation of Ser-354, Tyr-328, and Tyr-360 in Bcr and Bcr-Abl proteins. Tyrosine 89-92 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 121-128 11376433-6 2001 Using these antibodies, we established/confirmed the in vivo phosphorylation of Ser-354, Tyr-328, and Tyr-360 in Bcr and Bcr-Abl proteins. Tyrosine 102-105 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 121-128 11080615-5 2000 Overexpression of Y569W mutant Abl in 293T kidney cells produces a similar overall pattern of tyrosine phosphorylation as wild-type Abl, indicating that not all cellular proteins depend on Pro at P+3 for Abl recognition. Tyrosine 94-102 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 31-34 11080615-8 2000 Thus, proper phosphorylation of Crk by Abl depends not only on the interaction of the Crk SH3 domain with the Abl polyproline region, but also on the recognition of amino acids surrounding tyrosine by the Abl catalytic domain. Tyrosine 189-197 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 39-42 11003655-9 2000 Finally, we demonstrate that tyrosine phosphorylation of endogenous Abi-1 in fibroblasts is induced by both v-Abl and serum stimulation, further suggesting a role for Abi-1 in signal transduction initiated by v-Abl and growth factors. Tyrosine 29-37 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 108-113 11003655-9 2000 Finally, we demonstrate that tyrosine phosphorylation of endogenous Abi-1 in fibroblasts is induced by both v-Abl and serum stimulation, further suggesting a role for Abi-1 in signal transduction initiated by v-Abl and growth factors. Tyrosine 29-37 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 209-214 10833515-7 2000 Further, stimulation of untransformed cells with H(2)O(2) or pervanadate increased tyrosine phosphorylation of each of the most prominent known substrates of BCR/ABL, including c-ABL, c-CBL, SHC, and SHP-2. Tyrosine 83-91 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 158-165 10833515-7 2000 Further, stimulation of untransformed cells with H(2)O(2) or pervanadate increased tyrosine phosphorylation of each of the most prominent known substrates of BCR/ABL, including c-ABL, c-CBL, SHC, and SHP-2. Tyrosine 83-91 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 177-182 10833515-8 2000 Treatment of the BCR/ABL-expressing cell line MO7/p210 with the reducing agents pyrrolidine dithiocarbamate or N-acetylcysteine reduced the accumulation of ROS and also decreased tyrosine phosphorylation of cellular proteins. Tyrosine 179-187 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 17-24 10688886-6 2000 We have found that p62(dok) is directly tyrosine phosphorylated by p210(bcr-abl), and the sites of phosphorylation are located in the C-terminal half of the p62(dok) molecule. Tyrosine 40-48 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 72-79 10887132-2 2000 The Bcr/Abl fusion protein is a constitutively active tyrosine kinase that stimulates several intracellular signaling pathways, including activation of Ras through direct binding of the SH2-containing adapter protein Grb2 to Bcr tyrosine 177. Tyrosine 54-62 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 4-11 10829062-2 2000 Here we report that the kinase-deficient Src (SrcKD) directly inhibits the tyrosine phosphorylation of Cbl and other cellular proteins by Abl. Tyrosine 75-83 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 138-141 10896159-0 2000 Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Tyrosine 49-57 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 22-27 10896159-4 2000 Active c-Abl kinase leads to Cdk5 tyrosine phosphorylation, and this phosphorylation is enhanced by Cables. Tyrosine 34-42 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 7-12 10896159-5 2000 Phosphorylation of Cdk5 by c-Abl occurs on tyrosine 15 (Y15), which is stimulatory for p35/Cdk5 kinase activity. Tyrosine 43-51 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 27-32 10837221-7 2000 Moreover, our findings demonstrate that exposure of cells to ionizing radiation induces tyrosine phosphorylation of hTERT by a c-Abl-dependent mechanism. Tyrosine 88-96 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 127-132 10803516-5 2000 Tyrosine phosphorylation of cellular proteins was markedly reduced in BCR/ABL transformed cells after 16 h at 39 degrees C, whereas the expression of BCR/ABL was unchanged. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 70-77 10763825-6 2000 In addition, c-Crk II and CRKL are tyrosine phosphorylated and complexed with numerous other tyrosine phosphorylated proteins in Tel-Abl expressing Ba/F3 cells. Tyrosine 35-43 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 133-136 10763825-6 2000 In addition, c-Crk II and CRKL are tyrosine phosphorylated and complexed with numerous other tyrosine phosphorylated proteins in Tel-Abl expressing Ba/F3 cells. Tyrosine 93-101 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 133-136 9872323-8 1998 Our results suggest that the unique structure of Gads regulates its interaction with downstream SH3 domain-binding proteins and that Gads may function to couple tyrosine-phosphorylated proteins such as Shc, Bcr-Abl and activated receptor tyrosine kinases to downstream effectors distinct from Sos and Ras. Tyrosine 161-169 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 207-214 10706130-6 2000 Similarly, tyrosine phosphorylation of kinase-inactive Fes was observed after coexpression with active Bcr-Abl. Tyrosine 11-19 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 103-110 11721366-0 1999 [Effects of As2O3 on the BCR/ABL protein tyrosine phosphorylation in K562 cells]. Tyrosine 41-49 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 25-32 11721366-3 1999 RESULTS: Tyrosine phosphorylation of several cellular proteins especially BCR/ABL protein was decreased by 1 mumol/L As2O3, but not by 0.1 mumol/L As2O3. Tyrosine 9-17 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 74-81 10391251-4 1999 c-Abl phosphorylates p73 on a tyrosine residue at position 99 both in vitro and in cells that have been exposed to ionizing radiation. Tyrosine 30-38 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 10391678-0 1999 Tyrosine phosphorylation of C-Cbl facilitates adhesion and spreading while suppressing anchorage-independent growth of V-Abl-transformed NIH3T3 fibroblasts. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 119-124 10339507-4 1999 AG957, a member of the tyrphostin compounds, exerts a selective inhibition of p210(BCR/ABL) tyrosine phosphorylation. Tyrosine 92-100 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 83-90 10392900-0 1999 Nuclear c-Abl is a COOH-terminal repeated domain (CTD)-tyrosine (CTD)-tyrosine kinase-specific for the mammalian RNA polymerase II: possible role in transcription elongation. Tyrosine 55-63 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 8-13 10392900-1 1999 The c-Abl tyrosine kinase has been shown to interact with the COOH-terminal repeated domain (CTD) of mammalian RNA polymerase II and can phosphorylate the tyrosine residues in the CTD. Tyrosine 10-18 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 4-9 10392900-5 1999 In vivo, coexpression of a full length CTD prevents c-Abl from inducing the tyrosine phosphorylation of endogenous RNA polymerase II, and such inhibitory effect was not observed with the coexpression of COOH-terminal-truncated CTD. Tyrosine 76-84 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 52-57 10392900-9 1999 The activation of the HIV promoter required the nuclear localization of c-Abl and could be correlated with increased tyrosine phosphorylation of RNA polymerase II. Tyrosine 117-125 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 72-77 10194451-2 1999 We describe here the purification and mass spectrometric identification of a 155-kD tyrosine phosphorylated protein associated with src homologous and collagen gene (SHC) from p210(bcr/abl)-expressing hematopoietic cells as SHIP2, a recently reported, unique SH2-domain-containing protein closely related to phosphatidylinositol polyphosphate 5-phosphatase SHIP. Tyrosine 84-92 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 185-188 10194128-5 1999 However, these BCR-ABL mutants transform myeloid cells to growth factor independence, and in these cells CRKL is tyrosine phosphorylated and associates with BCR-ABL. Tyrosine 113-121 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 15-22 9874796-2 1999 The binding appeared to be required for XPB to be tyrosine-phosphorylated by BCR-ABL. Tyrosine 50-58 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 77-84 10637231-0 2000 A nuclear tyrosine phosphorylation circuit: c-Jun as an activator and substrate of c-Abl and JNK. Tyrosine 10-18 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 83-96 10637231-3 2000 We found that active nuclear Abl efficiently phosphorylate c-Jun, a transcription factor not previously known to be tyrosine phosphorylated. Tyrosine 116-124 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 29-32 10588700-4 1999 We also show that EWS/WT1 can interact with, and is a substrate for, modification on tyrosine residues by c-Abl. Tyrosine 85-93 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 106-111 10588700-5 1999 Tyrosine phosphorylation of EWS/WT1 by c-Abl negatively regulates its DNA binding properties. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 39-44 10419904-4 1999 In BCR-Abl transformed K562 cells, STAT5A and 5B are constitutively phosphorylated on tyrosine and are transcriptionally active. Tyrosine 86-94 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 3-10 10215653-9 1999 Furthermore, reduced Bcr-Abl expression is reflected in significantly attenuated Bcr-Abl-mediated protein tyrosine phosphorylation. Tyrosine 106-114 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 21-28 10215653-9 1999 Furthermore, reduced Bcr-Abl expression is reflected in significantly attenuated Bcr-Abl-mediated protein tyrosine phosphorylation. Tyrosine 106-114 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 81-88 10212258-3 1999 Here we demonstrate that there is an I-R-induced Rad51 tyrosine phosphorylation, and this induction is dependent on both ATM and c-Abl. Tyrosine 55-63 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 129-134 9837937-8 1998 Tyrosine-phosphorylated mammalian Disabled can recruit nonreceptor tyrosine kinases, such as src and abl, to the cytoplasmic tails of the receptors to which it binds, suggesting a molecular pathway by which receptor/ligand interaction on the cell surface could generate an intracellular signal. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 37-40 9886328-6 1998 The presence of BCR-ABL provides an explanation for the constitutive tyrosine phosphorylation of CrkL in CML platelets. Tyrosine 69-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 16-23 9886328-7 1998 As no correlation was observed between platelet counts and platelet BCR-ABL protein expression, thrombocytosis or thrombocythaemia in CML cannot be explained by constitutive BCR-ABL-mediated CrkL tyrosine phosphorylation. Tyrosine 196-204 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 174-181 9642287-2 1998 We examined whether tyrosine 221, which has been shown to be phosphorylated by c-Abl, was phosphorylated also by other tyrosine kinases, such as epidermal growth factor (EGF) receptor. Tyrosine 20-28 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 79-84 9740329-0 1998 c-Abl proto-oncoprotein is expressed and tyrosine phosphorylated in human sperm cell. Tyrosine 41-49 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 9740329-5 1998 In the in vitro kinase assay using the Triton X-100-solubilized capacitated sperm preparation, the 95 kD protein was autophosphorylated at the tyrosine residues, which was inhibited in the presence of c-Abl mAb. Tyrosine 143-151 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 201-206 9740329-7 1998 These findings suggest that the c-Abl or c-Abl-like proteins are present in mature sperm cells that are tyrosine autophosphorylated and may have a role in human sperm cell function. Tyrosine 104-112 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 32-37 9740329-7 1998 These findings suggest that the c-Abl or c-Abl-like proteins are present in mature sperm cells that are tyrosine autophosphorylated and may have a role in human sperm cell function. Tyrosine 104-112 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 41-46 9710592-6 1998 In vivo and in vitro tryptic phosphopeptide mapping studies show that Crkl is phosphorylated on multiple tyrosine residues when overexpressed or when activated by Bcr-Abl. Tyrosine 105-113 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 163-170 9603926-4 1998 Several proteins that were phosphorylated on tyrosine were found to transiently co-precipitate with c-Abl during cell adhesion, and one was identified as the focal adhesion protein paxillin. Tyrosine 45-53 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 100-105 9464542-7 1998 BCR-ABL+ cells treated with ceramide also showed a rapid and sequential increase in the tyrosine phosphorylation of p210(BCR-ABL), p46-56SHC and p120Cbl. Tyrosine 88-96 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-7 9461559-5 1998 We show that c-Abl phosphorylates Rad51 on Tyr-54 in vitro. Tyrosine 43-46 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 13-18 9461588-0 1998 Modification of phosphatidylinositol 3-kinase SH2 domain binding properties by Abl- or Lck-mediated tyrosine phosphorylation at Tyr-688. Tyrosine 100-108 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 79-82 9461588-0 1998 Modification of phosphatidylinositol 3-kinase SH2 domain binding properties by Abl- or Lck-mediated tyrosine phosphorylation at Tyr-688. Tyrosine 128-131 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 79-82 9461588-1 1998 In cells expressing the oncogenic Bcr-Abl tyrosine kinase, the regulatory p85 subunit of phosphatidylinositol 3-kinase is phosphorylated on tyrosine residues. Tyrosine 42-50 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 34-41 9464542-7 1998 BCR-ABL+ cells treated with ceramide also showed a rapid and sequential increase in the tyrosine phosphorylation of p210(BCR-ABL), p46-56SHC and p120Cbl. Tyrosine 88-96 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 121-128 9389713-4 1997 In cell-based assays of ABL tyrosine phosphorylation, inhibition of ABL kinase activity was observed at concentrations similar to that reported for p210BCR-ABL. Tyrosine 28-36 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 24-27 9467953-2 1998 Tyrosine phosphorylated Bcr has dramatically reduced kinase activity, and tyrosine 360 of Bcr, which is one of the sites of phosphorylation by the Bcr-Abl oncoprotein, is required for transkinase activity (Liu et al., Mol. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 147-154 9467953-2 1998 Tyrosine phosphorylated Bcr has dramatically reduced kinase activity, and tyrosine 360 of Bcr, which is one of the sites of phosphorylation by the Bcr-Abl oncoprotein, is required for transkinase activity (Liu et al., Mol. Tyrosine 74-82 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 147-154 9467953-7 1998 Taken together with the kinase inhibitory effects of tyrosine phosphorylation of Bcr by Bcr-Abl, our studies with tyrosine to phenylalanine Bcr mutants indicate that the hydroxyl residues of tyrosines 328 and 360 play crucial roles in Bcr"s kinase activity. Tyrosine 53-61 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 88-95 9467953-7 1998 Taken together with the kinase inhibitory effects of tyrosine phosphorylation of Bcr by Bcr-Abl, our studies with tyrosine to phenylalanine Bcr mutants indicate that the hydroxyl residues of tyrosines 328 and 360 play crucial roles in Bcr"s kinase activity. Tyrosine 191-200 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 88-95 9389713-4 1997 In cell-based assays of ABL tyrosine phosphorylation, inhibition of ABL kinase activity was observed at concentrations similar to that reported for p210BCR-ABL. Tyrosine 28-36 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 68-71 9389713-4 1997 In cell-based assays of ABL tyrosine phosphorylation, inhibition of ABL kinase activity was observed at concentrations similar to that reported for p210BCR-ABL. Tyrosine 28-36 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 68-71 9202056-4 1997 p210(BCR/ABL) binds to actin, and several cytoskeletal proteins are tyrosine phosphorylated by this oncoprotein. Tyrosine 68-76 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 5-12 9393882-6 1997 In hematopoietic cells transformed by the BCR/ABL oncogene, this phosphatase complex was found to be constitutively present with both components heavily tyrosine phosphorylated. Tyrosine 153-161 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 42-49 21528234-6 1997 We found that SHP-1 was highly and constitutively tyrosine phosphorylated in 32DCl3 and TF-1 cells transfected with BCR-ABL expression vector. Tyrosine 50-58 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 116-123 9315092-8 1997 Shd was tyrosine phosphorylated in COS-7 cells co-transfected with Shd and c-Abl or Bcr-Abl. Tyrosine 8-16 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 75-80 9315092-8 1997 Shd was tyrosine phosphorylated in COS-7 cells co-transfected with Shd and c-Abl or Bcr-Abl. Tyrosine 8-16 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 84-91 9211900-4 1997 ArgBP2 associates with and is a substrate of Arg and v-Abl, and is phosphorylated on tyrosine in v-Abl-transformed cells. Tyrosine 85-93 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 97-102 9299869-15 1997 The fact that BCR-ABL contains tyrosine residues, an SH2 domain, an SH3 domain, and proline-rich sequences raises the possibility of multiple protein-protein interactions. Tyrosine 31-39 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 14-21 9195915-7 1997 Since CRKL, an SH2, SH3 domain-containing adapter protein is known to bind directly to BCR-ABL and also binds to tyrosine-phosphorylated c-CBL, the ability of CRKL to mediate a complex between c-CBL and BCR-ABL was examined. Tyrosine 113-121 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 87-94 9195915-7 1997 Since CRKL, an SH2, SH3 domain-containing adapter protein is known to bind directly to BCR-ABL and also binds to tyrosine-phosphorylated c-CBL, the ability of CRKL to mediate a complex between c-CBL and BCR-ABL was examined. Tyrosine 113-121 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 203-210 9376661-3 1997 BCR-ABL contains tyrosine residues, an SH2 domain, an SH3 domain, and proline-rich sequences. Tyrosine 17-25 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-7 9154822-3 1997 In v-abl-transformed cells the endogenous Raf-1 protein was phosphorylated on tyrosine and displayed high constitutive kinase activity. Tyrosine 78-86 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 3-8 9067577-3 1997 In cell lines transformed by BCR/ABL, CRKL was tyrosine phosphorylated, while CRK was not. Tyrosine 47-55 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 29-36 9144171-8 1997 Moreover, the amino-terminal domain of RIN1 directly associates with, and is tyrosine phosphorylated by, c-ABL. Tyrosine 77-85 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 105-110 8978305-1 1997 CRKL has previously been shown to be a major tyrosine phosphorylated protein in neutrophils of patients with BCR-ABL+ chronic myelogenous leukemia and in cell lines expressing BCR-ABL CRKL and BCR-ABL form a complex as demonstrated by coimmunoprecipitation and are capable of a direct interaction in a yeast two-hybrid assay. Tyrosine 45-53 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 109-116 8978305-5 1997 In cells expressing the proline deletion mutation of BCR-ABL, CRKL is still tyrosine phosphorylated and forms a complex with BCR-ABL as demonstrated by coimmunoprecipitation. Tyrosine 76-84 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 53-60 8668148-7 1996 Finally, we demonstrate that as with p130cas, transformation with the oncogene v-abl results in an increase in tyrosine phosphorylation on HEF1, mediated by a direct association between HEF1 and v-Abl. Tyrosine 111-119 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 79-84 8692915-3 1996 Treatment with ionizing radiation is associated with c-Abl-dependent tyrosine phosphorylation of SHPTP1. Tyrosine 69-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 53-58 8912843-5 1996 Bcr(64-413) was also resistant to tyrosine phosphorylation by either activated c-Abl or Bcr-Abl. Tyrosine 34-42 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 79-84 8912843-5 1996 Bcr(64-413) was also resistant to tyrosine phosphorylation by either activated c-Abl or Bcr-Abl. Tyrosine 34-42 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 88-95 8810278-2 1996 In primary samples from virtually all patients with CML or Ph+ALL, the CRKL adapter protein is tyrosine phosphorylated and physically associated with p210(BCR/ABL). Tyrosine 95-103 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 155-162 8810278-4 1996 We have previously shown that CRKL, but not the related adapter protein c-CRK, is tyrosine phosphorylated in cell lines transformed by BCR/ABL, and that CRKL binds to BCR/ABL through the CRKL-SH3 domains. Tyrosine 82-90 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 135-142 8810278-4 1996 We have previously shown that CRKL, but not the related adapter protein c-CRK, is tyrosine phosphorylated in cell lines transformed by BCR/ABL, and that CRKL binds to BCR/ABL through the CRKL-SH3 domains. Tyrosine 82-90 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 167-174 8810278-11 1996 These results suggest that the BCR/ABL oncogene could alter the function of p130(CAS) in at least three ways: tyrosine phosphorylation, inducing constitutive binding of CRKL to a domain in p130(CAS) containing Tyr-X-X-Pro motifs (substrate domain), and disrupting the normal interaction of p130(CAS) with the focal adhesion protein tensin. Tyrosine 110-118 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 31-38 8668148-7 1996 Finally, we demonstrate that as with p130cas, transformation with the oncogene v-abl results in an increase in tyrosine phosphorylation on HEF1, mediated by a direct association between HEF1 and v-Abl. Tyrosine 111-119 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 195-200 8668151-10 1996 Tyrosine phosphorylation of the coprecipitated RNAP II was again dependent on the presence of the CTD-ID in Abl. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 108-111 8622703-3 1996 We have previously demonstrated that the Bcr protein is tyrosine phosphorylated within first-exon sequences by the Bcr-Abl oncoprotein. Tyrosine 56-64 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 115-122 8637883-0 1996 p140/c-Abl that binds DNA is preferentially phosphorylated at tyrosine residues. Tyrosine 62-70 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 5-10 8637883-6 1996 p140/c-Abl is quantitatively the minor population, is heavily phosphorylated at both serine and tyrosine residues, and is active in autophosphorylation reactions. Tyrosine 96-104 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 5-10 8617726-7 1996 The unique non-phosphotyrosine-mediated binding of Shc may allow direct tyrosine phosphorylation of Shc by v-Abl and subsequent activation of the Ras pathway through assembly of a signaling complex with Grb2-mSos. Tyrosine 22-30 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 107-112 8604027-3 1996 Aggregation of Fc epsilon RI by IgE and anti-IgE, IgE and antigen, or anti-Fc epsilon RI monoclonal antibodies on ABL cells or on HBMB, led to increased tyrosine phosphorylation of 120-, 100-, 80-, 72-, 50- to 65-, and 38-kDa substrates. Tyrosine 153-161 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 114-117 8604027-6 1996 Stimulation of ABL cells for 1 min resulted in extracellular calcium-independent tyrosine phosphorylation and activation of p72syk. Tyrosine 81-89 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 15-18 8622703-5 1996 Moreover, Bcr tyrosine 360 is phosphorylated in vivo within both Bcr-Abl and Bcr. Tyrosine 14-22 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 65-72 8622703-8 1996 Tyrosine-phosphorylated Bcr, phosphorylated in vitro by Bcr-Abl, was greatly inhibited in its serine/threonine kinase activity, impairing both auto- and transkinase activities of Bcr. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 56-63 8632906-2 1996 When introduced into factor dependent hematopoietic cell lines, BCR/ABL induces the tyrosine phosphorylation of many cellular proteins. Tyrosine 84-92 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 64-71 8524328-8 1996 In NIH 3T3 cells transformed by Bcr-Abl, c-Cbl becomes strongly tyrosine phosphorylated and associates with c-Crk. Tyrosine 64-72 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 32-39 8524328-10 1996 These results indicate that Crk binds to c-Cbl in a tyrosine phosphorylation-dependent manner, suggesting a physiological role for the Crk-c-Cbl complex in Bcr-Abl tyrosine phosphorylation-mediated transformation. Tyrosine 52-60 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 156-163 8524328-10 1996 These results indicate that Crk binds to c-Cbl in a tyrosine phosphorylation-dependent manner, suggesting a physiological role for the Crk-c-Cbl complex in Bcr-Abl tyrosine phosphorylation-mediated transformation. Tyrosine 164-172 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 156-163 7566975-0 1995 Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Tyrosine 10-18 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 95-106 8524249-9 1995 This finding suggests that in Abl-transformed cells, more than one class of tyrosine-phosphorylated sites (those that bind the Grb2 SH2 domain and those that bind the Crk SH2 domain) can lead to Ras activation. Tyrosine 76-84 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 30-33 7478571-1 1995 The SH2/SH3 adaptor protein Crkl is abnormally phosphorylated on tyrosine by the Bcr/Abl protein in leukemic cells from patients with Philadelphia-chromosome (Ph)positive leukemia. Tyrosine 65-73 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 81-88 7556524-0 1995 Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 78-85 7566975-4 1995 In this study we examined tyrosine phosphorylation of focal adhesion proteins in cells expressing p210BCR/ABL. Tyrosine 26-34 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 98-109 7524758-9 1994 Our results suggest that pp39 CRKL in CML neutrophils may be stably tyrosine-phosphorylated by the BCR/ABL kinase at an early stage of myeloid differentiation when the ABL kinase is active. Tyrosine 68-76 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 103-106 7545163-2 1995 Abnormally tyrosine-phosphorylated substrates of the Bcr/Abl kinase in Ph-positive cells are likely to contribute to leukemogenesis by interfering with normal signal transduction pathways. Tyrosine 11-19 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 57-60 7545163-4 1995 In the current study, a tyrosine-phosphorylated protein with a molecular mass of approximately 120 kDa was identified which binds only to the Crkl Src homology 2 (SH2) domain in cells, including Ph-positive patient material, containing an active Bcr/Abl protein. Tyrosine 24-32 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 246-253 7533294-0 1995 Src homology 2 domain as a specificity determinant in the c-Abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain. Tyrosine 73-81 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 58-63 7533294-8 1995 The Abl SH2 domain binds the tyrosine-phosphorylated [Tyr(P)] CTD and is required for the processive and stoichiometric phosphorylation of the 52 tyrosines in the CTD. Tyrosine 29-37 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 4-7 7533294-8 1995 The Abl SH2 domain binds the tyrosine-phosphorylated [Tyr(P)] CTD and is required for the processive and stoichiometric phosphorylation of the 52 tyrosines in the CTD. Tyrosine 54-57 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 4-7 7533294-8 1995 The Abl SH2 domain binds the tyrosine-phosphorylated [Tyr(P)] CTD and is required for the processive and stoichiometric phosphorylation of the 52 tyrosines in the CTD. Tyrosine 146-155 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 4-7 7530656-0 1995 Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 133-144 7939633-4 1994 Bap-1 is a substrate for the Bcr serine-threonine kinase and is also phosphorylated on tyrosine by Bcr-Abl but not by c-Abl. Tyrosine 87-95 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 99-106 7521685-4 1994 Previous experiments have shown that CRKL is phosphorylated on tyrosine in the chronic myelogenous leukemia (CML) cell line K562 and that CRKL is a substrate for ABL and for BCR/ABL in COS-1 cells. Tyrosine 63-71 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 162-165 7521685-4 1994 Previous experiments have shown that CRKL is phosphorylated on tyrosine in the chronic myelogenous leukemia (CML) cell line K562 and that CRKL is a substrate for ABL and for BCR/ABL in COS-1 cells. Tyrosine 63-71 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 174-181 7521685-7 1994 In contrast, all BCR/ABL+ CML and acute lymphoblastic leukemia patient samples examined showed clear tyrosine-phosphorylation of CRKL. Tyrosine 101-109 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 17-24 7537361-2 1995 P210 BCR/abl tyrosine kinase induces tyrosine phosphorylation of Shc, and activation of p21ras and PI 3-Kinase. Tyrosine 13-21 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 5-12 7534303-3 1995 Both IL-3 and v-Abl stimulated the tyrosine phosphorylation of SHC and GTPase-activating protein. Tyrosine 35-43 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 14-19 7535279-2 1995 We report that the ena protein contains proline-rich motifs and binds to Abl and Src SH3 domains, ena is also a substrate for the Abl kinase; tyrosine phosphorylation of ena is increased when it is coexpressed in cells with human or Drosophila Abl and endogenous ena tyrosine phosphorylation is reduced in Abl mutant animals. Tyrosine 142-150 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 73-76 7535279-2 1995 We report that the ena protein contains proline-rich motifs and binds to Abl and Src SH3 domains, ena is also a substrate for the Abl kinase; tyrosine phosphorylation of ena is increased when it is coexpressed in cells with human or Drosophila Abl and endogenous ena tyrosine phosphorylation is reduced in Abl mutant animals. Tyrosine 267-275 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 73-76 8194526-2 1994 We have identified a kinase activity, which binds to the first Crk SH3 domain and phosphorylates c-Crk on tyrosine 221 (Y221), as c-Abl. Tyrosine 106-114 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 132-135 8164650-7 1994 We demonstrate that SH2 domains from other proteins (Ras-GTPase-activating protein, Src, p85 phosphatidylinositol 3-kinase subunit, and Crk) can complement the absence of the Abl SH2 domain and that mutants with heterologous SH2 domains induce altered patterns of tyrosine-phosphorylated proteins in vivo. Tyrosine 264-272 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 175-178 8153630-3 1994 Single point mutations in the Src-homology 2 (SH2) domain, the major tyrosine autophosphorylation site of the kinase domain, and the Grb-2 binding site in the Bcr region impaired the transformation of fibroblasts by Bcr-Abl. Tyrosine 69-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 216-223 1379843-3 1992 Tyrosine phosphorylated proteins with a molecular mass of 150 kDa (p150) and 115 kDa (p110) were found in both K-562 and MR-87. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 67-71 7926767-5 1994 When bound to Abl, Crk-I was phosphorylated on tyrosine. Tyrosine 47-55 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 14-17 7926759-8 1994 Together these data demonstrate that the v-abl protein specifically interferes with light-chain gene rearrangement by suppressing at least two pathways essential for this stage of B-cell differentiation and suggest that tyrosine phosphorylation is important in regulating RAG gene expression. Tyrosine 220-228 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 41-46 8119916-0 1994 p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes. Tyrosine 52-60 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-11 8119916-7 1994 v-abl expression was also found to increase the tyrosine phosphorylation of p93c-Fes. Tyrosine 48-56 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 7508932-5 1994 A Shc-associated 140-kDa protein was identified, which was phosphorylated on tyrosine residues transiently after cytokine stimulation and constitutively after expression of p210BCR/ABL. Tyrosine 77-85 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 173-184 8112292-8 1994 In vitro, the Grb2 SH2 domain bound Bcr-Abl through recognition of a tyrosine phosphorylation site within the amino-terminal bcr-encoded sequence (p.Tyr177-Val-Asn-Val), that is common to both Bcr-Abl proteins. Tyrosine 69-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 36-43 1383690-6 1992 Binding of tyrosine-phosphorylated c-ABL 1b by the relatively high-affinity ABL and ARG SH2 domains was quantitatively analyzed, and equilibrium dissociation constants for both interactions were estimated to be in the range of 5 x 10(-7) M. The ABL SH2 domain exhibited relatively high affinity for phosphotyrosine-free BCR as well; however, this interaction appears to be about two orders of magnitude weaker than binding of tyrosine-phosphorylated c-ABL 1b. Tyrosine 306-314 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 35-40 1383690-6 1992 Binding of tyrosine-phosphorylated c-ABL 1b by the relatively high-affinity ABL and ARG SH2 domains was quantitatively analyzed, and equilibrium dissociation constants for both interactions were estimated to be in the range of 5 x 10(-7) M. The ABL SH2 domain exhibited relatively high affinity for phosphotyrosine-free BCR as well; however, this interaction appears to be about two orders of magnitude weaker than binding of tyrosine-phosphorylated c-ABL 1b. Tyrosine 306-314 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 76-79 8402896-5 1993 Binding of GRB-2 to BCR-ABL is mediated by the direct interaction of the GRB-2 SH2 domain with a phosphorylated tyrosine, Y177, within the BCR first exon. Tyrosine 112-120 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 20-27 8336729-5 1993 This class of ABL mutants shows increased tyrosine phosphorylation of cellular proteins in vivo but low levels of autophosphorylation. Tyrosine 42-50 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 14-17 8334997-4 1993 In the presence of hormone, the c-Abl:ER fusion protein was transforming, cytoplasmic and tyrosine phosphorylated, whereas it was non-transforming, nuclear and hypophosphorylated without hormone. Tyrosine 90-98 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 32-37 8441409-3 1993 In this work, we show that two other structural requirements for full transforming activity of P210 BCR/ABL include a functional tyrosine kinase and the presence of tyrosine 1294, a site of autophosphorylation within the tyrosine kinase domain. Tyrosine 129-137 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 100-107 8423987-0 1993 BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon. Tyrosine 8-16 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-7 8423987-3 1993 We now report that tryptic peptides shared by both P160 BCR and P210 BCR-ABL are phosphorylated on tyrosine in vitro either when using immune complexes containing P160 BCR complexed to BCR-ABL or when P160 BCR is phosphorylated in trans by P210 BCR-ABL immune complexes from cells lacking functional P160 BCR. Tyrosine 99-107 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 69-76 8423987-3 1993 We now report that tryptic peptides shared by both P160 BCR and P210 BCR-ABL are phosphorylated on tyrosine in vitro either when using immune complexes containing P160 BCR complexed to BCR-ABL or when P160 BCR is phosphorylated in trans by P210 BCR-ABL immune complexes from cells lacking functional P160 BCR. Tyrosine 99-107 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 185-192 8423987-3 1993 We now report that tryptic peptides shared by both P160 BCR and P210 BCR-ABL are phosphorylated on tyrosine in vitro either when using immune complexes containing P160 BCR complexed to BCR-ABL or when P160 BCR is phosphorylated in trans by P210 BCR-ABL immune complexes from cells lacking functional P160 BCR. Tyrosine 99-107 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 185-192 8423987-5 1993 As with P210 BCR-ABL, P160 BCR tyrosine phosphopeptides were shared with P185 BCR-ABL, indicating that the major sites of tyrosine phosphorylation in vitro are contained within the first exon of P160 BCR. Tyrosine 122-130 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 78-85 8423987-6 1993 Similarly, BCR-ABL autophosphorylation was found to occur predominantly at tyrosines within BCR exon 1 sequences. Tyrosine 75-84 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 11-18 8423987-7 1993 These results raise the possibility that the activated ABL protein kinase of BCR-ABL proteins modulates the putative signal transduction activities of P160 BCR by tyrosine phosphorylation of exon 1 sequences. Tyrosine 163-171 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 55-58 8423987-7 1993 These results raise the possibility that the activated ABL protein kinase of BCR-ABL proteins modulates the putative signal transduction activities of P160 BCR by tyrosine phosphorylation of exon 1 sequences. Tyrosine 163-171 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 77-84 1383690-6 1992 Binding of tyrosine-phosphorylated c-ABL 1b by the relatively high-affinity ABL and ARG SH2 domains was quantitatively analyzed, and equilibrium dissociation constants for both interactions were estimated to be in the range of 5 x 10(-7) M. The ABL SH2 domain exhibited relatively high affinity for phosphotyrosine-free BCR as well; however, this interaction appears to be about two orders of magnitude weaker than binding of tyrosine-phosphorylated c-ABL 1b. Tyrosine 11-19 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 35-40 1383690-6 1992 Binding of tyrosine-phosphorylated c-ABL 1b by the relatively high-affinity ABL and ARG SH2 domains was quantitatively analyzed, and equilibrium dissociation constants for both interactions were estimated to be in the range of 5 x 10(-7) M. The ABL SH2 domain exhibited relatively high affinity for phosphotyrosine-free BCR as well; however, this interaction appears to be about two orders of magnitude weaker than binding of tyrosine-phosphorylated c-ABL 1b. Tyrosine 11-19 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 37-40 1383690-6 1992 Binding of tyrosine-phosphorylated c-ABL 1b by the relatively high-affinity ABL and ARG SH2 domains was quantitatively analyzed, and equilibrium dissociation constants for both interactions were estimated to be in the range of 5 x 10(-7) M. The ABL SH2 domain exhibited relatively high affinity for phosphotyrosine-free BCR as well; however, this interaction appears to be about two orders of magnitude weaker than binding of tyrosine-phosphorylated c-ABL 1b. Tyrosine 11-19 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 76-79 1383690-6 1992 Binding of tyrosine-phosphorylated c-ABL 1b by the relatively high-affinity ABL and ARG SH2 domains was quantitatively analyzed, and equilibrium dissociation constants for both interactions were estimated to be in the range of 5 x 10(-7) M. The ABL SH2 domain exhibited relatively high affinity for phosphotyrosine-free BCR as well; however, this interaction appears to be about two orders of magnitude weaker than binding of tyrosine-phosphorylated c-ABL 1b. Tyrosine 11-19 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 450-455 1643641-8 1992 When tested in Abelson murine leukemia virus-transformed BALB/c cell, active benzopyranone and benzothiopyranone derivatives inhibited tyrosine phosphorylation of cellular proteins by the v-abl tyrosine protein kinase. Tyrosine 135-143 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 188-193 2910452-4 1989 In order to understand the relationship between induction of differentiation and reduction of tyrosine phosphorylation by the c-abl gene product, the effect that herbimycin A, a selective inhibitor of intracellular tyrosine kinase activity, exerts on the differentiation of K562 cells was examined. Tyrosine 94-102 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 126-131 1737071-8 1992 Phosphoamino acid analysis of immunoprecipitated, autophosphorylated baculovirus derived c-Abl protein indicates that the majority of label incorporated is on the tyrosine residues. Tyrosine 163-171 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 89-94 1712111-1 1991 Phosphotyrosine cannot be detected on normal human ABL protein-tyrosine kinases, but activated oncogenic forms of the human ABL protein are phosphorylated on tyrosine in vivo. Tyrosine 7-15 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 124-127 19891780-0 2009 Cbl-associated protein is tyrosine phosphorylated by c-Abl and c-Src kinases. Tyrosine 26-34 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 53-58 19891780-5 2009 RESULTS: We here show that CAP is Tyr phosphorylated by and interacts with both c-Abl and c-Src. Tyrosine 34-37 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 80-85 19891780-9 2009 Our findings suggest that coordinated action of Src and Abl might regulate the function of CAP and reveal a functional role especially for the Src-mediated Tyr phosphorylation of CAP in cell spreading. Tyrosine 156-159 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 56-59 10822173-4 2000 Expression of Bcr-Abl induced tyrosine phosphorylation of both Dok1 and SHIP1 and the formation of a Dok1/SHIP1 complex. Tyrosine 30-38 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 14-21 10822173-5 2000 Tyr(P) SHIP1 was also bound to Shc in Bcr-Abl expressing cells. Tyrosine 0-3 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 38-45 34816484-7 2022 Post-mortem studies of PD patients demonstrate increased levels of tyrosine phosphorylated alpha-synuclein, consistent with the activation of c-Abl in human disease. Tyrosine 67-75 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 142-147 34431498-6 2021 We identified tyrosines in the juxtamembrane region of EphB6 as EphB4 substrates, which can bind the SH2 domains of signalling effectors, including Abl, Src and Vav3, consistent with cellular roles in recruiting these proteins for downstream signaling. Tyrosine 14-23 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 148-151 34205064-4 2021 Among them, Src and Abl target CagA and stimulate tyrosine phosphorylation of the latter at its EPIYA-motifs. Tyrosine 50-58 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 20-23 34136397-4 2021 Additionally, we show that the RUNX2 transcriptional activity is dependent on the number of its tyrosine residues that are phosphorylated by ABL. Tyrosine 96-104 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 141-144 35193953-5 2022 We identified that RtcB, the tRNA ligase responsible for XBP1 mRNA splicing, is tyrosine-phosphorylated by c-Abl and dephosphorylated by PTP1B. Tyrosine 80-88 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 107-112 3010299-3 1986 The minor allele, b, is due to a deletion of about 500 base pairs in an intron located downstream of the codon for the phosphate-acceptor tyrosine residue of the c-abl gene product. Tyrosine 138-146 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 162-167 2431286-3 1986 The p210 protein was also recognized by antisera against v-abl-encoded polypeptides and displayed kinase activity, phosphorylating itself on tyrosine, in an immunocomplex kinase assay. Tyrosine 141-149 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 57-62 2431286-9 1986 Enhanced tyrosine phosphorylation of cellular proteins is thus a feature shared by cells transformed by v-abl and cells expressing a rearranged bcr-abl gene. Tyrosine 9-17 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 104-109 2431286-9 1986 Enhanced tyrosine phosphorylation of cellular proteins is thus a feature shared by cells transformed by v-abl and cells expressing a rearranged bcr-abl gene. Tyrosine 9-17 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 144-151 2420727-0 1986 Protein phosphorylation at tyrosine residues in v-abl transformed mouse lymphocytes and fibroblasts. Tyrosine 27-35 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 48-53 2420727-10 1986 These data show that, upon v-abl-induced transformation, phosphorylation at tyrosine takes place also on proteins other than the 160 or 120-kDa oncogene products. Tyrosine 76-84 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 27-32 2420727-11 1986 In lymphocytes and fibroblasts these proteins are different, suggesting that the cascade of events triggered by the v-abl gene in different cell types involves tyrosine phosphorylation of different specific proteins. Tyrosine 160-168 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 116-121 6191223-3 1983 In the present study, sequences encoding the tyrosine phosphorylation acceptor sites of the Abelson murine leukaemia virus oncogene, v-abl, and its human cellular homologue, c-abl, have been identified and their nucleic acid sequences determined. Tyrosine 45-53 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 174-179 3879812-8 1985 Comparison of in vitro and in vivo tyrosine phosphorylation sites of the abl proteins suggests that they function differently in vivo. Tyrosine 35-43 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 73-76 2982232-3 1985 One antiserum was made against a polypeptide overlapping the in vivo tyrosine phosphorylation site of murine P120gag-abl and what is believed to be a homologous tyrosine phosphorylation site of the predicted normal human c-abl gene product (v-abl 263-280). Tyrosine 69-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 117-120 2982232-7 1985 Immune complex kinase assays using conditions that allow the tyrosine phosphorylation of P120gag-abl showed that in vitro phosphorylation of P190 and P240 occurs primarily at tyrosine residues. Tyrosine 61-69 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 97-100 33932144-3 2021 In this study, we demonstrate that c-Abl highly phosphorylates FHL2 at Y97, Y176, Y217 and Y236 through mass spectrometry and tyrosine-to-phenylalanine (Y F) mutant analysis. Tyrosine 126-134 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 35-40 33328764-6 2020 Increased tyrosine phosphorylation in multiple receptor/protein tyrosine kinases (EPHA2, EGFR, IGF1R, ABL1 and LYN) was identified in CNE2-IR vs CNE2 cells. Tyrosine 10-18 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 102-106 33075386-6 2021 Western blotting confirmed that tyrosine phosphorylation in STAT5, a substrate of ABL1, was enhanced, and the novel mutation was proved to be a gain-of-function mutation. Tyrosine 32-40 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 82-86 32468042-0 2020 c-Abl-mediated tyrosine phosphorylation of DNA damage response proteins and implications in important cellular functions (Review). Tyrosine 15-23 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 33284894-2 2020 We aimed to investigate whether it was possible to promote pro/pre-B cell maturation beyond this phase and make them sensitive to imatinib treatment by overexpressing immunoregulatory tyrosine activation motif (ITAM) with BCR-ABL in a Ph+ B-ALL mouse model. Tyrosine 184-192 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 222-229 33163944-5 2020 Active c-Abl induces TFEB phosphorylation on tyrosine and the inhibition of this kinase promotes lysosomal biogenesis, autophagy, and exocytosis. Tyrosine 45-53 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 7-12 33163944-7 2020 Thus, c-Abl is a TFEB regulator that mediates its tyrosine phosphorylation, and the inhibition of c-Abl activates TFEB promoting cholesterol clearance in NPC models. Tyrosine 50-58 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 6-11 32439698-8 2020 RPPA analysis revealed that such resistance emanates from signaling of tyrosine 821 of AXL via the tyrosine kinase c-ABL. Tyrosine 71-79 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 115-120 32439698-10 2020 CONCLUSIONS: Collectively, the studies presented herein suggest that tyrosine 821 of AXL mediates resistance to cetuximab by activation of c-ABL kinase in HNSCC and that targeting of both EGFR and c-ABL leads to a robust anti-tumor response. Tyrosine 69-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 139-144 32439698-10 2020 CONCLUSIONS: Collectively, the studies presented herein suggest that tyrosine 821 of AXL mediates resistance to cetuximab by activation of c-ABL kinase in HNSCC and that targeting of both EGFR and c-ABL leads to a robust anti-tumor response. Tyrosine 69-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 197-202 33019757-5 2020 Upon irradiation and synemin inhibition, c-Abl hyperphosphorylation on tyrosine (Y) 412 and threonine (T) 735 was significantly reduced, prompting us to hypothesize that c-Abl tyrosine kinase is an important signaling component of the synemin-mediated radioresistance pathway. Tyrosine 71-79 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 41-46 32606017-2 2020 The non-receptor tyrosine kinases FYN and ABL are known to drive phosphorylation of tyrosine residues in YXXP motifs within the intracellular domains of DCBLD family members, which leads to the recruitment of the Src homology 2 (SH2) domain of the adaptors CT10 regulator of kinase (CRK) and CRK-like (CRKL). Tyrosine 17-25 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 42-45 31833784-1 2020 The availability of several BCR-ABL1 tyrosine kinase inhibitor (TKI) options means physicians and patients can select the most appropriate treatment for a patient with chronic myeloid leukemia (CML). Tyrosine 37-45 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 28-35 31767149-1 2020 Tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the standard first-line therapy for patients with chronic-phase CML. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 46-53 32078113-0 2020 Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia. Tyrosine 50-58 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 41-48 30621530-0 2020 Oxidative stress-induced activation of Abl and Src kinases rapidly induces P-glycoprotein internalization via phosphorylation of caveolin-1 on tyrosine-14, decreasing cortisol efflux at the blood-brain barrier. Tyrosine 143-151 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 39-42 30621530-7 2020 A brain perfusion study in rats showed that cortisol efflux at the BBB was markedly decreased by H2O2 administration, and inhibitors of Abl kinase and Src kinase, which phosphorylate tyrosine-14 in caveolin-1, suppressed this decrease. Tyrosine 183-191 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 136-139 30621530-8 2020 Overall, these findings support the idea that oxidative stress-induced activation of Abl kinase and Src kinase induces internalization of P-gp via the phosphorylation of tyrosine-14 in caveolin-1, leading to a rapid decrease of P-gp-mediated cortisol efflux at the BBB. Tyrosine 170-178 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 85-88 31563145-2 2020 There have been successful examples of targeted therapy improving the outcome of some childhood cancers, such as the addition of an ABL class tyrosine kinase inhibitor to conventional chemotherapy substantially improving the cure rate for patients with BCR-ABL1 positive acute lymphoblastic leukemia. Tyrosine 142-150 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 132-135 31399521-4 2020 Further analyses of murine cell lines and primary patient material indicate that active BCR-ABL directly interacts with Beclin-1 and phosphorylates its tyrosine residues 233 and 352, resulting in autophagy suppression. Tyrosine 152-160 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 88-95 31944221-1 2020 Importance: A randomized clinical trial is needed to determine whether the second-generation Abl-tyrosine kinase inhibitor dasatinib is more effective than the first-generation inhibitor imatinib mesylate for childhood Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Tyrosine 97-105 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 93-96 31901955-1 2020 PURPOSE: ABL tyrosine kinase inhibitors (TKIs) have demonstrated potency in the treatment of chronic myeloid leukemia (CML) patients. Tyrosine 13-21 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 9-12 31952182-2 2020 Although tyrosine kinase inhibitors (TKIs) against BCR-ABL represent the standard therapeutic option for CML, resistances to TKIs can be a serious problem. Tyrosine 9-17 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 51-58 31807112-3 2019 Since the development of the tyrosine kinase inhibitor of the BCR-ABL kinase, the clinical approach to CML has dramatically changed, with a stunning improvement in the quality of life and response rates of patients. Tyrosine 29-37 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 62-69 31765938-1 2020 Chronic myelogenous leukemia (CML) is caused by the BCR-ABL chimeric tyrosine kinase, which is derived from the reciprocal translocation, t(9;22)(q34;q11). Tyrosine 69-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 52-59 31765938-2 2020 BCR-ABL tyrosine kinase inhibitors (TKIs) can provide prolonged overall survival in CML patients, resulting in life expectancy nearly to general population, and now approximately half of patients who achieved deep molecular response (DMR) can sustain durable molecular remission after discontinuation TKIs. Tyrosine 8-16 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-7 31862885-3 2019 Here, we show that PM mechanoadaptation is controlled by a tension-sensing pathway composed of c-Abl tyrosine kinase and membrane curvature regulator FBP17. Tyrosine 101-109 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 95-100 31861239-1 2019 Signal transducers and activators of transcription 5A and 5B (STAT5A and STAT5B) are crucial downstream effectors of tyrosine kinase oncogenes (TKO) such as BCR-ABL in chronic myeloid leukemia (CML) and FLT3-ITD in acute myeloid leukemia (AML). Tyrosine 117-125 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 157-164 31615652-4 2019 In addition, morphine alleviated the anti-proliferative and pro-apoptotic effects of BCR-ABL tyrosine kinase inhibitor (TKI) in BP-CML cells. Tyrosine 93-101 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 85-92 31808889-1 2019 Subsequent to the development and global availability of BCR/ABL-targeted tyrosine kinase inhibitors (TKIs), the prognosis of patients with chronic myeloid leukemia (CML), at least those in the chronic phase, has markedly improved, and in the developed world, the average lifespan of these patients is now close to that of age- and sex-matched subjects without the disease. Tyrosine 74-82 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 57-64 31760572-4 2019 Management and outcomes of patients with chronic myeloid leukemia have been revolutionized by the discovery, development, and approval of BCR-ABL tyrosine kinase inhibitors (TKIs). Tyrosine 146-154 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 138-145 31717629-1 2019 Chronic Myeloid Leukemia (CML) is a disease arising in stem cells expressing the BCR-ABL oncogenic tyrosine kinase that transforms one Hematopoietic stem/progenitor Cell into a Leukemic Stem Cell (LSC) at the origin of differentiated and proliferating leukemic cells in the bone marrow (BM). Tyrosine 99-107 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 81-88 31717629-2 2019 CML-LSCs are recognized as being responsible for resistances and relapses that occur despite the advent of BCR-ABL-targeting therapies with Tyrosine Kinase Inhibitors (TKIs). Tyrosine 140-148 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 107-114 31759365-3 2019 Our aim is to explore regions outside the BCR-ABL oncoprotein to identify potential therapeutic targets to curb drug resistance by targeting growth factor receptor-bound protein-2 (Grb-2) which binds to BCR-ABL at the phosphorylated tyrosine (Y177) thereby activating the Ras and PI3K/AKT signaling pathway. Tyrosine 233-241 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 203-210 31683623-1 2019 Tyrosine kinase inhibitors (TKI) such as the BCR-ABL inhibitor dasatinib and nilotinib are highly effective therapies for chronic myeloid leukemia (CML). Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 45-52 31759365-3 2019 Our aim is to explore regions outside the BCR-ABL oncoprotein to identify potential therapeutic targets to curb drug resistance by targeting growth factor receptor-bound protein-2 (Grb-2) which binds to BCR-ABL at the phosphorylated tyrosine (Y177) thereby activating the Ras and PI3K/AKT signaling pathway. Tyrosine 233-241 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 42-49 31428968-0 2019 BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of Survivin and Cyclin D1 in chronic myeloid leukemia cells. Tyrosine 16-24 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-7 31428968-7 2019 These results suggest that BCR-ABL induces tyrosine phosphorylation of YAP presumably through Src family kinases, which results in expression of Survivin and Cyclin D leading to leukemogenesis in CML cells. Tyrosine 43-51 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 27-34 30174304-2 2018 Here, we show that oncogenic HER2 tyrosine kinase signaling induces phosphorylation of mitochondrial creatine kinase 1 (MtCK1) on tyrosine 153 (Y153) in an ABL-dependent manner in breast cancer cells. Tyrosine 34-42 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 156-159 31399520-0 2019 c-Abl-Mediated Tyrosine Phosphorylation of PARP1 Is Crucial for Expression of Proinflammatory Genes. Tyrosine 15-23 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 31700719-12 2019 It also discusses the successful utilization of tyrosine kinase inhibitors (TKIs) in the treatment of BCR-ABL-positive AML, as there are no established guidelines. Tyrosine 48-56 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 102-109 31100317-4 2019 Here, we show that the interaction between PLEKHG2 and ABL1 attenuated the PLEKHG2-induced serum response element-dependent gene transcription in a tyrosine phosphorylation-independent manner. Tyrosine 148-156 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 55-59 30659095-6 2019 Here, we present the first crystal structures of tyrosine-phosphorylated human SH3 domains derived from the Abelson-family kinases ABL1 and ABL2 at 1.6 and 1.4 A resolutions, respectively. Tyrosine 49-57 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 131-135 30478172-9 2019 The inhibition of the RAD51-ABL1 complex also suppressed downstream RAD51 Tyr-315 phosphorylation. Tyrosine 74-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 28-32 30177833-0 2019 Desuppression of TGF-beta signaling via nuclear c-Abl-mediated phosphorylation of TIF1gamma/TRIM33 at Tyr-524, -610, and -1048. Tyrosine 102-105 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 48-53 30177833-5 2019 Replacement of the three tyrosine residues Tyr-524, -610, and -1048 with phenylalanine (3YF) inhibits c-Abl-mediated phosphorylation of TIF1gamma and enhances TIF1gamma"s association with Smad3. Tyrosine 25-33 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 102-107 30177833-5 2019 Replacement of the three tyrosine residues Tyr-524, -610, and -1048 with phenylalanine (3YF) inhibits c-Abl-mediated phosphorylation of TIF1gamma and enhances TIF1gamma"s association with Smad3. Tyrosine 43-46 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 102-107 30177833-7 2019 Intriguingly, activation of c-Abl by epidermal growth factor (EGF) induces desuppression of TGF-beta signaling via enhancing the tyrosine phosphorylation level of TIF1gamma. Tyrosine 129-137 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 28-33 30177833-9 2019 These results suggest that nuclear c-Abl-mediated tyrosine phosphorylation of TIF1gamma has a desuppressive role in TGF-beta-Smad2/3 signaling. Tyrosine 50-58 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 35-40 28087699-3 2017 Here we report that the c-Abl non-receptor kinase phosphorylates DDB1 at residue Tyr-316 to recruit a small regulatory protein, DDA1, leading to increased substrate ubiquitination. Tyrosine 81-84 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 24-29 30165626-8 2018 In addition, c-Abl directly interacted with GSK3beta and catalyzed its phosphorylation at tyrosine 216, and their interaction was enhanced under MPP+ treatment. Tyrosine 90-98 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 13-18 29730354-5 2018 c-Abl-mediated tyrosine phosphorylation in the Runx1 transcription inhibition domain negatively regulated the transcriptional activity of Runx1 and inhibited Runx1-mediated MK maturation. Tyrosine 15-23 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 31723781-7 2018 For example, in 1 poor risk subtype, known as Ph-like/BCR-ABL1-like ALL, approximately 10% have rearrangements of ABL-class tyrosine kinases: including ABL1, ABL2, PDGFRB, PDGFRA, and CSF1R. Tyrosine 124-132 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 58-62 31723781-7 2018 For example, in 1 poor risk subtype, known as Ph-like/BCR-ABL1-like ALL, approximately 10% have rearrangements of ABL-class tyrosine kinases: including ABL1, ABL2, PDGFRB, PDGFRA, and CSF1R. Tyrosine 124-132 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 152-156 31723769-1 2018 Dasatinib is an ABL1 tyrosine kinase inhibitor (TKI) with a short in vivo plasmatic half-life but with good efficiency, which is not fully understood. Tyrosine 21-29 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 16-20 29487179-4 2018 Vinculin targeting requires its phosphorylation at tyrosine 822 by Abl family kinases (hereafter Abl), but the origin of force-dependent Abl activation had not been identified. Tyrosine 51-59 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 67-70 29487179-4 2018 Vinculin targeting requires its phosphorylation at tyrosine 822 by Abl family kinases (hereafter Abl), but the origin of force-dependent Abl activation had not been identified. Tyrosine 51-59 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 97-100 29487179-4 2018 Vinculin targeting requires its phosphorylation at tyrosine 822 by Abl family kinases (hereafter Abl), but the origin of force-dependent Abl activation had not been identified. Tyrosine 51-59 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 97-100 29066624-0 2017 Active site-adjacent phosphorylation at Tyr-397 by c-Abl kinase inactivates caspase-9. Tyrosine 40-43 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 51-56 29066624-4 2017 Caspase-9 phosphorylation by the non-receptor tyrosine kinase c-Abl at Tyr-153 reportedly leads to caspase-9 activation. Tyrosine 71-74 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 62-67 29066624-7 2017 Instead, we identified a new site for c-Abl-mediated phosphorylation, Tyr-397. Tyrosine 70-73 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 38-43 29066624-9 2017 Our results further indicate that Tyr-397 is the dominant site of c-Abl phosphorylation both in vitro and upon c-Abl activation in cells. Tyrosine 34-37 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 66-71 29066624-9 2017 Our results further indicate that Tyr-397 is the dominant site of c-Abl phosphorylation both in vitro and upon c-Abl activation in cells. Tyrosine 34-37 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 111-116 28666867-0 2017 Enhancement of TGF-beta-induced Smad3 activity by c-Abl-mediated tyrosine phosphorylation of its coactivator SKI-interacting protein (SKIP). Tyrosine 65-73 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 50-55 28428613-4 2017 In this report, we identify Abl-mediated phosphorylation of a highly conserved Tyr residue in the P + 1 loop of protein kinase D2 (PKD2) during oxidative stress. Tyrosine 79-82 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 28-31 29807053-0 2018 c-Abl phosphorylation of Yin Yang 1"s conserved tyrosine 254 in the spacer region modulates its transcriptional activity. Tyrosine 48-56 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 29807053-5 2018 Both radioactive and non-radioactive in vitro kinase assays, as well as co-immunoprecipitation in different cell lines, show that the target of c-Abl phosphorylation is tyrosine residue 254. Tyrosine 169-177 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 144-149 29341593-0 2018 Analysis of Cellular Tyrosine Phosphorylation via Chemical Rescue of Conditionally Active Abl Kinase. Tyrosine 21-29 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 90-93 29022905-4 2017 In this study, we found that c-Abl phosphorylated Drp1 at tyrosine 266, 368 and 449 in vitro and in vivo, which augmented the GTPase activity of Drp1 and promoted Drp1-mediated mitochondrial fragmentation. Tyrosine 58-66 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 29-34 28578803-3 2017 Based on our previous findings indicating c-Abl hyperphosphorylation on tyrosine (Y) 412 and threonine (T) 735 upon beta1-integrin inhibition, we hypothesized c-Abl tyrosine kinase as an important mediator of beta1-integrin signaling for radioresistance. Tyrosine 72-80 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 42-47 28578803-3 2017 Based on our previous findings indicating c-Abl hyperphosphorylation on tyrosine (Y) 412 and threonine (T) 735 upon beta1-integrin inhibition, we hypothesized c-Abl tyrosine kinase as an important mediator of beta1-integrin signaling for radioresistance. Tyrosine 72-80 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 159-164 28378189-5 2017 Serine and tyrosine phosphorylation of galectin-3 by c-Abl, CKI, and GSK-3beta could regulate its localization and associated signal transduction. Tyrosine 11-19 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 53-58 27883218-2 2017 In this study, we analyzed tyrosine phosphorylation of FoxA1 by the non-receptor-type tyrosine kinase c-Abl. Tyrosine 27-35 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 102-107 28486134-0 2017 Abl Regulates Planar Polarized Junctional Dynamics through beta-Catenin Tyrosine Phosphorylation. Tyrosine 72-80 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-3 28288113-6 2017 We overexpressed the mutant constructs in HEK 293T cells and observed increased tyrosine phosphorylation, suggesting increased ABL1 kinase activities associated with both the p.Tyr245Cys and p.Ala356Thr substitutions. Tyrosine 80-88 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 127-131 28279034-9 2017 Conclusion: ACA often emerged during the disease progress in CML patients, regular and timely detection of chromosomes karyotype and ABL tyrosine point mutations during TKI treatment was important for therapeutic evaluation, progress and prognosis of CML. Tyrosine 137-145 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 133-136 27161995-5 2016 The analysis suggests that tyrosine phosphorylation of SH3 domains found in Abl kinases act as a switch that can induce both the loss and, unexpectedly, gain of affinity for proline-rich ligands. Tyrosine 27-35 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 76-79 27845183-6 2017 This change of partners is under the control of a tyrosine phosphorylation of Mtx1 by c-Abl. Tyrosine 50-58 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 86-91 27228340-14 2016 Furthermore, immunofluorescence assay demonstrated that Tyr-99 of nuclear P73 was phosphorylated accompanied with nuclear entrapment of BCR-ABL after transfection with RanGAP1 shRNA or miR-1301 in IM-treated K562 cells. Tyrosine 56-59 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 136-143 27348587-8 2016 Furthermore, in vitro studies show that c-Abl phosphorylation of alpha-synuclein at tyrosine 39 enhances alpha-synuclein aggregation. Tyrosine 84-92 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 40-45 27018250-5 2016 The major tyrosine phosphorylation sites on RBM39 that are phosphorylated by c-Abl are Y95 and Y99, as demonstrated by liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS) and mutational analysis. Tyrosine 10-18 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 77-82 27078848-9 2016 Furthermore, CRKL tyrosine phosphorylation was inhibited by dasatinib (an inhibitor of ABL and SRC kinases), which in combination with the ALK inhibitor crizotinib displayed a synergistic inhibitory effect in vitro. Tyrosine 18-26 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 87-90 26866052-1 2016 This article expands on crystal structure data for human H-RAS with mutations at position Y137, briefly described in a paper on the effects of phosphorylation of Y137 by ABL kinases (Tyrosine phosphorylation of RAS by ABL allosterically enhances effector binding, published in the FASEB Journal [1]). Tyrosine 183-191 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 170-173 27757426-0 2016 TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1. Tyrosine 14-22 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 89-93 27757426-5 2016 Nuclear TIE2 binds to key components of DNA repair and phosphorylates H4 at tyrosine 51, which, in turn, is recognized by the proto-oncogene ABL1, indicating a role for nuclear TIE2 as a sensor for genotoxic stress by action as a histone modifier. Tyrosine 76-84 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 141-145 27757426-6 2016 H4Y51 constitutes the first tyrosine phosphorylation of core histones recognized by ABL1, defining this histone modification as a direct signal to couple genotoxic stress with the DNA repair machinery. Tyrosine 28-36 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 84-88 26866052-1 2016 This article expands on crystal structure data for human H-RAS with mutations at position Y137, briefly described in a paper on the effects of phosphorylation of Y137 by ABL kinases (Tyrosine phosphorylation of RAS by ABL allosterically enhances effector binding, published in the FASEB Journal [1]). Tyrosine 183-191 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 218-221 26217035-0 2015 c-Abl-mediated tyrosine phosphorylation of JunB is required for Adriamycin-induced expression of p21. Tyrosine 15-23 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 26697169-8 2015 Furthermore, exposure of HLMVECs to HGF or S1P stimulated c-Abl-mediated tyrosine phosphorylation of paxillin at Y31 and Y118 in a time-dependent fashion, and down-regulation of c-Abl with siRNA attenuated HGF- or S1P-mediated lamellipodia formation, translocation of p47 (phox) to lamellipodia, and endothelial barrier enhancement. Tyrosine 73-81 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 58-63 26697169-10 2015 Together, these results suggest that c-Abl-mediated tyrosine phosphorylation of paxillin at Y31 and Y118 regulates HGF- or S1P-mediated lamellipodia formation, ROS generation in lamellipodia, and endothelial permeability. Tyrosine 52-60 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 37-42 26217035-5 2015 We first analysed phosphorylation sites of JunB and found that c-Abl majorly phosphorylates JunB at Tyr(173), Tyr(182) and Tyr(188). Tyrosine 100-103 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 63-68 26217035-5 2015 We first analysed phosphorylation sites of JunB and found that c-Abl majorly phosphorylates JunB at Tyr(173), Tyr(182) and Tyr(188). Tyrosine 110-113 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 63-68 26217035-5 2015 We first analysed phosphorylation sites of JunB and found that c-Abl majorly phosphorylates JunB at Tyr(173), Tyr(182) and Tyr(188). Tyrosine 110-113 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 63-68 25999467-0 2015 Tyrosine phosphorylation of RAS by ABL allosterically enhances effector binding. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 35-38 25999467-5 2015 Here we report that ABL phosphorylates tyrosine 137 of H-, K-, and NRAS. Tyrosine 39-47 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 20-23 25999467-6 2015 Increased RIN1 levels enhanced HRAS-Tyr(137) phosphorylation by nearly 5-fold, suggesting that RAS-stimulated RIN1 can drive ABL-mediated RAS modification in a feedback circuit. Tyrosine 36-39 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 125-128 26310847-5 2015 Moreover, ROS1, HCK, ABL1, ABL2, JAK3, LCK and TYR03 were identified as candidate kinases responsible for the phosphorylation of Tyr(136) of LIX1L. Tyrosine 129-132 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 21-25 26134485-5 2015 Proximity-driven intramolecular azo coupling was showcased in cyclization of a beta-hairpin peptide, structural features of the azo linked cyclic peptide was elucidated by NMR, and intermolecular azo coupling was achieved between an SH3 protein Abl-SH3 and its polyproline peptide ligands at specific tyrosine residues. Tyrosine 301-309 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 245-248 26126715-8 2015 When coexpressed in HEK293T cells, ABL phosphorylated DGCR8 at Tyr(267). Tyrosine 63-66 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 35-38 26235616-0 2015 c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells. Tyrosine 15-23 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 26126715-11 2015 These results reveal a new pathway in the DNA damage response wherein ABL-dependent tyrosine phosphorylation of DGCR8 stimulates the processing of selective primary miRNAs. Tyrosine 84-92 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 70-73 25770215-5 2015 Tyrosine phosphorylation of AKAP8 is induced by several tyrosine kinases, such as Src, Fyn, and c-Abl but not Syk. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 96-101 25795725-0 2015 c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury. Tyrosine 15-23 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 25795725-9 2015 Together, these results suggest that c-Abl mediated tyrosine phosphorylation of paxillin at Y31 and Y118 regulates LPS-mediated pulmonary vascular permeability and injury. Tyrosine 52-60 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 37-42 25043303-5 2015 We show that phosphorylation of tyrosines 295 and 361 of Dok1 by Abl family kinases suppresses CrkI transforming activity, and that upon phosphorylation these tyrosines bind the SH2 domains of the Ras inhibitor p120 RasGAP. Tyrosine 32-41 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 65-68 24759597-3 2014 S116836 at low concentrations used in the present study mildly downregulates auto-tyrosine phosphorylation of Bcr-Abl. Tyrosine 82-90 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 110-117 25249015-1 2015 The SH2-containing adaptor protein Grb10 was first identified in a yeast screen as a new binding partner for BCR-ABL and associates with BCR-ABL in a tyrosine-dependent manner. Tyrosine 150-158 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 109-116 25249015-1 2015 The SH2-containing adaptor protein Grb10 was first identified in a yeast screen as a new binding partner for BCR-ABL and associates with BCR-ABL in a tyrosine-dependent manner. Tyrosine 150-158 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 137-144 25527332-0 2015 The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Tyrosine 65-73 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 4-11 25694432-0 2015 The interaction of protein-tyrosine phosphatase alpha (PTPalpha) and RACK1 protein enables insulin-like growth factor 1 (IGF-1)-stimulated Abl-dependent and -independent tyrosine phosphorylation of PTPalpha. Tyrosine 27-35 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 139-142 25694432-5 2015 We found that PTPalpha binds to the scaffold protein RACK1 and that RACK1 coordinates the IGF-1 receptor, PTPalpha, and Abl in a complex to enable IGF-1-stimulated and Abl-dependent PTPalpha-Tyr-789 phosphorylation. Tyrosine 191-194 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 120-123 25082234-6 2015 It can bind to BCR-ABL in the cytosol, where it is phosphorylated on tyrosine residues, and it maintains the proper compartmentalization in the nuclear bodies, where it acts as part of a PML network to regulate PTEN de-ubiquitination. Tyrosine 69-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 15-22 25821558-6 2015 Tyrosine phosphorylation of Bcr-Abl showed a dose-dependent decrease in 32Dp210T315I following AUY922 treatment for 16h. Tyrosine 0-8 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 28-35 25264277-6 2014 We demonstrate that the mechanism of p27(KIP1) stabilization relied on inhibition of p27(KIP1) phosphorylation on tyrosine residues by c-Abl. Tyrosine 114-122 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 135-140 25264277-7 2014 We provide evidence that in neuroblastoma cell lines a significant fraction of cellular c-Abl is phosphorylated on Tyr-245, consistent with an open and active conformation. Tyrosine 115-118 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 88-93 25201268-1 2014 Abelson tyrosine-protein kinase 1 (ABL1) catalysed phosphorylation involves the addition of a phosphate group from ATP to the tyrosine residue on the substrate abltide. Tyrosine 8-16 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 35-39 24913448-5 2014 We demonstrate that LASP1 is specifically phosphorylated by BCR-ABL at tyrosine-171 in CML patients, which is abolished by tyrosine kinase inhibitor therapy. Tyrosine 71-79 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 60-67 24412932-6 2014 In vitro studies demonstrate that c-Abl directly interacts with alpha-syn and catalyzes its phosphorylation mainly at tyrosine 39 (pY39) and to a lesser extent at tyrosine 125 (pY125). Tyrosine 118-126 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 34-39 24412932-6 2014 In vitro studies demonstrate that c-Abl directly interacts with alpha-syn and catalyzes its phosphorylation mainly at tyrosine 39 (pY39) and to a lesser extent at tyrosine 125 (pY125). Tyrosine 163-171 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 34-39 24836440-5 2014 Although BCR-ABL induces STAT5-tyrosine phosphorylation independent of JAK2-kinase activity, BCR-ABL is less efficient in inducing active STAT5A:STAT5B-heterodimerization than IL-3, leaving constitutive STAT5A and STAT5B-homodimerization unaffected. Tyrosine 31-39 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 9-16 24317448-5 2014 We further demonstrate that BCR-ABL physically interacts with and phosphorylates HAUSP on tyrosine residues to trigger its activity. Tyrosine 90-98 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 28-35 24786396-1 2014 c-Abl is activated in the brain of Parkinson"s disease (PD) patients and in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated mice where it inhibits parkin through tyrosine phosphorylation leading to the accumulation of parkin substrates, and neuronal cell death. Tyrosine 178-186 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 24445143-4 2014 We report that IRF5 is expressed in CML cells, where it interacts with the BCR-ABL kinase that modulates its expression and induces its tyrosine phosphorylation. Tyrosine 136-144 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 75-82 24445143-6 2014 Interestingly, a mutant devoid of a BCR-ABL consensus site (IRF5(Y104F)) still presented significant tyrosine phosphorylation. Tyrosine 101-109 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 36-43